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===================

###### Health education compared to usual practice

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ----------------------------------------------------------------------------- -------------- -----------------------
  **Comparison 1: health education compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  **Population:** adolescents and parents  **Setting:** Sweden and USA  i**ntervention:** health education  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **Impact**                      **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                

  **Absolute effects\* (95% CI)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Relative effect  (95% CI)**   **Narrative results**                                                                                                                                                        

  **With usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **With health education**                                                                                                                                                                                    

  **Uptake of HPV vaccine^a^**                                                                                                                                                                                                                                                                                                                                                                                                                                                                             209 per 1000                    298 per 1000  (242 to 367)         **RR 1.43**  (1.16 to 1.76)                  Health education improves uptake of HPV vaccine compared to usual practice.   1054  (3)^b^   ⊕⊕⊕⊕  **High**^c,d,e^

  **CI:** confidence interval; **HPV:** human papillomavirus; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  \***The anticipated absolute effect in the intervention group** (and its 95% confidence interval) is based on the assumed likelihood of being vaccinated in the usual care group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  \*\***GRADE Working Group grades of evidence.**:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ----------------------------------------------------------------------------- -------------- -----------------------

^a^ The lag‐time between delivery of the intervention and assessment of outcomes ranged from three months ([Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}) to 11 months ([Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"} )

^b^[Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"} (randomised trial); [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"} (cluster‐randomised trial); [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"} (cluster‐randomised trial).  ^c^ Well conducted randomised trials with consistent findings (I^2^ = 0%).

^d^ The findings from the one non‐randomised trial that assessed this comparison were similar to the findings of the randomised trials.

^e^One study reported that health education did not have any adverse events in relation to usual practice ([Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}).

###### Complex compared to simplified health education

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- -----------------------
  **Comparison 2: complex compared to simplified health education**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Population:** adolescents  **Setting:** Australia  **Intervention:** multi‐component health education^a^  **Comparison:** simplified health education                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **Outcomes**                                                                                                                                                                                                                                                           **Impact**                          **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                                                                                                                            

  **Absolute effects\* (95% CI)**                                                                                                                                                                                                                                        **Relative effect  (95% CI)**       **Narrative results**                                                                                                                                                                                                                                                                    

  **With simplified education**                                                                                                                                                                                                                                          **With complex health education**                                                                                                                                                                                                                                                                                            

  **Uptake of hepatitis B vaccine^b^**                                                                                                                                                                                                                                   756 per 1000                        741 per 1000  (726 to 748)         **RR 0.98**  (0.96 to 0.99)                  A complex multi‐component health education programme probably results in little or no difference in uptake of 3 doses of hepatitis B vaccine compared to simplified health education.   17,411  (1)^c^   ⊕⊕⊕⊝  **Moderate^d^**

  **CI:** confidence interval; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  \***The anticipated absolute effect in the intervention group** (and its 95% confidence interval) is based on the assumed likelihood of being vaccinated in the simplified health education group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                                                                                                                
  \*\***GRADE Working Group grades of evidence**:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                                                                                 
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- -----------------------

^a^ Health education kit with 4‐lesson structured multi‐component intervention that included: a resource fact sheet and assessment, an information video and questions designed to engage an adolescent audience, small group discussion, and an activity to locate resource information on the Internet.

^b^The lag‐time between delivery of the intervention and assessment of outcomes was not provided.

^c^[Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"} (randomised trial).  ^d^ Downgraded one level due to study limitations, as the included study has an unclear risk of bias.

###### Financial incentives compared to usual practice

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------ ------------- --------------------
  **Comparison 3: financial incentives compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                   

  **Patient or population:** adolescents  **Setting:** UK  i**ntervention:** financial incentive^a^  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                   

  **Outcomes**                                                                                                                                                                                                                     **Impact**                      **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                      

  **Absolute effects\* (95% CI)**                                                                                                                                                                                                  **Relative effect  (95% CI)**   **Narrative results**                                                                                                                                                              

  **With usual practice**                                                                                                                                                                                                          **With financial incentives**                                                                                                                                                                                      

  **Uptake of HPV vaccine^b^**                                                                                                                                                                                                     196 per 1000                    284 per 1000  (206 to 390)         **RR 1.45**  (1.05 to 1.99)                  Financial incentives may improve uptake of HPV vaccine compared to usual practice.   500  (1)^c^   ⊕⊕⊝⊝  **Low**^d,e^

  **CI:** confidence interval; **HPV:** human papillomavirus; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                    
  \***The anticipated absolute effect in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the usual practice group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                      
  **\*\*GRADE Working Group grades of evidence.**:\                                                                                                                                                                                                                                                                                                                                                                                                   
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                  
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                              
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                        
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                 
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------ ------------- --------------------

^a^The financial incentive involved an offer of shopping vouchers worth GBP 45 upon completion of 3 HPV vaccination doses.

^b^The lag‐time between delivery of the intervention and assessment of outcomes was one to seven months. Invitation letters promising incentives were sent in February‐March of 2010 and vaccination sessions were conducted between March and September 2010

^c^[Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"} (randomised trial).  ^d^ Downgraded one level for study limitations (unclear risk of bias in the included study).  ^e^ Downgraded one level for imprecision of findings.

###### Health education plus financial incentives compared to usual practice

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ---------------------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------------
  **Comparison 4: health education plus financial incentives compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Population:** adolescents and parents  **Setting:** USA  **Intervention:** health education plus financial incentives^a^  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                                                                                

  **Outcomes**                                                                                                                                                                                                                      **Impact**                                 **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                                                                                                

  **Absolute effects\* (95% CI)**                                                                                                                                                                                                   **Relative effect  (95% CI)**              **Narrative results**                                                                                                                                                                                                                                        

  **With usual practice**                                                                                                                                                                                                           **With health education and incentives**                                                                                                                                                                                                                                                                

  **Uptake of hepatitis B vaccine^b^**                                                                                                                                                                                              451 per 1000                               622 per 1000  (433 to 902)         **RR 1.38**  (0.96 to 2.00)                  We are uncertain about the effects of health education plus financial incentives on the uptake of 3 doses of hepatitis B vaccine compared to usual practice.   104  (1)^c^   ⊕⊝⊝⊝  **Very low**^d,e,f^

  **CI:** confidence interval; **HPV:** human papillomavirus; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  \***The anticipated absolute effects in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the usual practice group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                                                                                           
  **\*\*GRADE Working Group grades of evidence:**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                                                                        
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                                                                                    
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                                                              
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                       
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ---------------------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------------

^a^The intervention involved (1) an educational video and PowerPoint presentation for caregivers and adolescents about hepatitis B infection and the importance of hepatitis B vaccination, (2) free vaccination, and (3) financial incentives. When the adolescents received each vaccine dose, their caregivers were given cash incentives of USD 10 for the first dose, USD 10 for the second dose, and USD 30 for the third dose. In addition, at each visit, adolescents and caregivers were given gift packages containing cosmetics for adults and sweets and toothbrushes for the children.

^b^The lag‐time between delivery of the intervention and assessment of outcomes was three months.

^c^[Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"} (randomised trial).  ^d^ Downgraded one level for serious study limitations (unclear risk of bias in the included study).  ^e^ Downgraded two levels for imprecision of findings with a wide confidence interval that includes both benefit and harm as well as a very small number of participants.

^f^ Downgraded two levels for serious indirectness, given that this finding is based on one small study from one setting.

###### Mandatory vaccination versus usual practice

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -----------------------
  **Comparison 5: mandatory vaccination vs usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Population:** adolescents  **Setting:** USA  **Intervention:** school entry law mandating vaccination  **Comparison:** usual practice in other classes in the same schools                                                                                                                                                                                                                                                                                                                                                                                     

  **Outcomes**                                                                                                                                                                                                                       **Impact**                       **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                                                                                                                                

  **Absolute effects\* (95% CI)**                                                                                                                                                                                                    **Relative effect  (95% CI)**    **Narrative results**                                                                                                                                                                                                                                                                        

  **With usual practice**                                                                                                                                                                                                            **With mandatory vaccination**                                                                                                                                                                                                                                                                                                

  **Uptake of hepatitis B vaccine^a^**                                                                                                                                                                                               248 per 1000                     728 per 1000  (677 to 784)         **RR 2.94**  (2.66 to 3.25)                  Mandatory vaccination probably leads to a large increase in uptake of 3 doses of the hepatitis B vaccine compared to usual practice in other classes in the same schools.                     2642  (1)^b^   ⊕⊕⊕⊝  **Moderate**^d^

  **Population:** adolescents  **Setting:** USA  **Intervention:** school entry law mandating vaccination  **Comparison:** usual practice in areas not affected by the mandatory vaccination law                                                                                                                                                                                                                                                                                                                                                                   

  **Uptake of hepatitis B vaccine^a^**                                                                                                                                                                                               186 per 1000                     728 per 1000\                      **RR 3.92**\                                 Mandatory vaccination probably leads to a large increase in uptake of 3 doses of the hepatitis B vaccine compared to usual practice in areas not affected by the mandatory vaccination law.   6462  (1)^c^   ⊕⊕⊕⊝  **Moderate**^d^
                                                                                                                                                                                                                                                                      (678 to 780)                       (3.65 to 4.20)                                                                                                                                                                                                                                            

  **CI:** confidence interval; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  \***The anticipated absolute effects in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the no‐intervention group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                                                                                                                 
  \*\***GRADE Working Group grades of evidence**:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                                                                                               
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                                                                                                           
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                                                                                     
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                                              
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -----------------------

^a^ The lag‐time between delivery of the intervention and assessment of outcomes was 6‐8 years.

^b^[Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"} (non‐randomised trial) compared students in the ninth grade (affected by the hepatitis B law) and 12th grade (not affected by the law) in the state of Missouri .  ^c^[Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"} (non‐randomised trial) compared the ninth grade in the state of Missouri (affected by the hepatitis B vaccination law) to the ninth grade in the state of Kansas (not affected by the law).

^d^ As a non‐randomised trial, these outcomes were initially graded as low certainty evidence and then upgraded by one level for very large effect sizes.

###### Provider prompts compared to usual practice

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- -----------------------
  **Comparison 6: provider prompts compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                         

  **Population:** healthcare workers  **Setting:** USA  **Intervention:** provider prompts^a^  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                                           

  **Outcomes**                                                                                                                                                                                                                      **Impact**                     **№ of participants  (studies)**                                                                                                                        **Certainty of the evidence  (GRADE)\*\***   

  **Relative effect  (95% CI)**                                                                                                                                                                                                     **Narrative results**                                                                                                                                                                                                               

  **Uptake of HPV vaccine^b^**                                                                                                                                                                                                      a**OR 0.99**\                  Provider prompts probably make little or no difference to uptake of 3 doses of HPV vaccine among adolescents compared to usual practice.                859  (2)^c^                                  ⊕⊕⊕⊝  **Moderate**^d^
                                                                                                                                                                                                                                    (0.55 to 1.81)^e^                                                                                                                                                                                                                   

  **Uptake of Tdap vaccine^b^**                                                                                                                                                                                                     a**OR 1.28**\                  Provider prompts probably make little or no difference to uptake of Tdap vaccine among adolescents compared to usual practice.                          3296  (2)^c^                                 ⊕⊕⊕⊝  **Moderate**^d^
                                                                                                                                                                                                                                    (0.59 to 2.80)                                                                                                                                                                                                                      

  **Uptake of meningococcal conjugate vaccine^b^**                                                                                                                                                                                  a**OR 1.09** ,(0.67 to 1.79)   Provider prompts probably make little or no difference to uptake of the meningococcal conjugate vaccine among adolescents compared to usual practice.   3219  (2)^c^                                 ⊕⊕⊕⊝  **Moderate**^d^

  **Uptake of seasonal influenza vaccine^b^**                                                                                                                                                                                       **aOR 0.91**\                  Provider prompts probably make little or no difference to uptake of the seasonal influenza vaccine among adolescents compared to usual practice.        1439  (2)^c^                                 ⊕⊕⊕⊝  **Moderate**^d^
                                                                                                                                                                                                                                    (0.61 to 1.34)                                                                                                                                                                                                                      

  **CI:** confidence interval; **HPV:** human papillomavirus; **aOR:** adjusted odds ratio; **Tdap:** tetanus--diphtheria--acellular--pertussis.\                                                                                                                                                                                                                                                                                                                       
  \***The anticipated absolute effects in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the usual practice group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                       
  **\*\*GRADE Working Group grades of evidence.**:\                                                                                                                                                                                                                                                                                                                                                                                                                     
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                    
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                          
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                   
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- -----------------------

^a^ When a healthcare provider opened a patient\'s electronic medical record, there was a screen display of the list of vaccines that were due at that visit. At the beginning of the study, a 1‐2 hour educational session was given to the providers to inform them about the electronic health record based prompts.

^b^The lag‐time between delivery of the intervention and assessment of outcomes was 12 months.

^c^[Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"} conducted two separate randomised trials, one in a local and one in a national network, and then reported these in one paper.  ^d^ Downgraded one level for imprecision of findings.

^e^ All odds ratios were adjusted based on a multilevel mixed‐effect logistic regression model with covariates for pair assignment, study time period, group assignment, and an interaction between time and group assignment.

###### Provider education with performance feedback compared to usual practice

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------
  **Comparison 7: provider education with performance feedback compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Population:** paediatricians and nurse practitioners  **Setting:** USA  **Intervention:** education with performance feedback  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Outcomes**                                                                                                                                                                          **Impact**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\***

  **Uptake of HPV vaccination^a^**                                                                                                                                                      Provider education with performance feedback may increase the proportion of adolescents who are offered and accept HPV vaccination by clinicians, compared to usual practice. Compared to adolescents visiting non‐participating clinicians (in the usual practice group), the adolescents visiting clinicians in the intervention group were more likely to receive the first dose of HPV during preventive visits (5.7 percentage points increase) and during acute visits (0.7 percentage points for the first and 5.6 percentage points for the second doses of HPV).   \> 200,000 children  (1 CBA)^b^    ⊕⊕⊝⊝  **Low**^c^

  **HPV:** human papillomavirus; **CBA**: controlled before‐after study\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  \***GRADE Working Group grades of evidence:**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------

^a^ There was no lag‐time between delivery of the intervention and assessment of outcomes. The intervention period ran from 01 January to 30 November 2013. Outcomes were assessed throughout this period, starting from day 1.

^b^[Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"} (controlled before‐after study).  c This is a non‐randomised study.

###### Class‐based compared to age‐based HPV vaccination in schools

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------- -----------------------
  **Comparison 8: class‐based compared to age‐based HPV vaccination in schools**                                                                                                                                                                                                                                                                                                                                                                                          

  **Population:** adolescents  **Setting:** Tanzania  **Intervention:** class‐based vaccination  **Comparison:** age‐based vaccination                                                                                                                                                                                                                                                                                                                                    

  **Outcomes**                                                                                                                                                                                                                  **Impact**                      **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                                             

  **Absolute effects\* (95% CI)**                                                                                                                                                                                               **Relative effect  (95% CI)**   **Narrative results**                                                                                                                                                                                     

  **With age‐based delivery**                                                                                                                                                                                                   **With class‐based delivery**                                                                                                                                                                                                             

  **HPV vaccine uptake^a^**                                                                                                                                                                                                     721 per 1000                    786 per 1000  (764 to 815)         **RR 1.09**  (1.06 to 1.13)                  Class‐based vaccination probably leads to slightly higher HPV vaccine uptake than age‐based vaccination.   5537  (1)^b^   ⊕⊕⊕⊝  **Moderate**^c^

  **CI:** confidence interval; **HPV:** human papillomavirus; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                        
  \***The anticipated absolute effects in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the comparison group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                             
  **\*\*GRADE Working Group grades of evidence**:\                                                                                                                                                                                                                                                                                                                                                                                                                        
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                      
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                  
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                            
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                     
  ^†^Substantially different = a large enough difference that it might affect a decision                                                                                                                                                                                                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------- -----------------------

^a^ The lag‐time between delivery of the intervention and assessment of outcomes was 12 months.

^b^[Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"} (cluster‐randomised trial).  ^c^ Downgraded one level for indirectness, given that the outcome is based on one study from one setting.

###### Multi‐component provider intervention compared to usual practice

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------
  **Comparison 9: multi‐component provider intervention compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Population:** healthcare providers and their adolescent patients (boys and girls aged 11--21 years)  **Setting:** USA  **Intervention:** multi‐component performance improvement continuing medical education intervention^a^  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Outcomes**                                                                                                                                                                                                                                                                                                                          **Impact**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\***

  **HPV vaccine uptake^b^**                                                                                                                                                                                                                                                                                                             A multi‐component provider intervention (including an education session, repeated contacts, individualised feedback, and incentives) probably improves uptake of HPV vaccine compared to usual practice. Girls in the intervention group are probably more likely to receive their next HPV vaccine dose than those in the comparison group (odds ratio 1.6, 95% CI 1.1 to 2.2). The effects are probably larger for boys (odds ratio 25.00, 95% CI 15.00 to 40.00), and this may be because publicly funded HPV vaccination for boys became available during the study.   15,849 adolescents  (1)^c^         ⊕⊕⊕⊝  **Moderate**^d^

  **HPV:** human papillomavirus.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  \***GRADE Working Group grades of evidence:**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------

^a^The intervention involved: (1) 6--8 education visits over 12 months by an HPV physician‐educator; (2) focused education sessions on HPV‐related topics designed to change the way providers viewed the importance of HPV vaccination and responded to parents\' hesitation toward HPV vaccines; (3) individualised feedback where providers and practices received individual reports that showed their performance compared to other providers in their practice on HPV vaccination coverage; and (4) quality improvement incentives whereby physicians were eligible to receive maintenance‐of‐registration credits, which fulfilled requirements for maintaining board certification.

^b^ The lag‐time between delivery of the intervention and assessment of outcomes was six months.

^c^[Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"} (cluster‐randomised trial).  ^d^ Downgraded one level because of serious indirectness, given that this finding is based on one study from one setting.

###### Multi‐component provider and parent intervention compared to usual practice

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------
  **Comparison 10: multi‐component provider and parent intervention compared to usual practice**                                                                                                                                                                                                                                                                                                                                                                                                   

  **Population:** healthcare workers and parents  **Setting:** USA  **Intervention:** multi‐component provider and parent intervention^a^  **Comparison:** usual practice                                                                                                                                                                                                                                                                                                                          

  **Outcomes**                                                                                                                                                                                              **Impact**                          **№ of participants  (studies)**   **Certainty of the evidence  (GRADE)\*\***                                                                                                                                                                      

  **Absolute effects\* (95% CI)**                                                                                                                                                                           **Relative effect  (95% CI)**       **Narrative results**                                                                                                                                                                                                                              

  **With usual practice**                                                                                                                                                                                   **With multi‐faced intervention**                                                                                                                                                                                                                                                      

  **HPV vaccine uptake at 3 months**                                                                                                                                                                        25 per 1,000                        57 per 1000\                       **RR 2.34**\                                 A multi‐component intervention involving healthcare providers and parents may improve uptake of the HPV vaccine compared to usual practice.   337  (1)^b^\         ⊕⊕⊝⊝  **Low**^d^
                                                                                                                                                                                                                                                (18 to 180)                        (0.75 to 7.32)                                                                                                                                                                             *Randomised trial*   

  **HPV vaccine uptake at 6 months**                                                                                                                                                                        52 per 1,000                        73 per 1000\                       **RR 1.41**\                                 25,869  (1)^c^*Non‐randomised trial*                                                                                                          ⊕⊕⊝⊝  **Low**^e^     
                                                                                                                                                                                                                                                (65 to 83)                         (1.25 to 1.59)                                                                                                                                                                                                  

  **CI:** confidence interval; **HPV:** human papillomavirus; **RR:** risk ratio.\                                                                                                                                                                                                                                                                                                                                                                                                                 
  \***The risk in the intervention group** (and its 95% CI) is based on the likelihood of being vaccinated in the usual practice group and the **relative effect** of the intervention (and its 95% CI).\                                                                                                                                                                                                                                                                                          
  **\*\*GRADE Working Group grades of evidence**:\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  **High certainty:** this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is low.\                                                                                                                                                                                                                                                                                                                               
  **Moderate certainty:** this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different^†^ is moderate.\                                                                                                                                                                                                                                                                                                                           
  **Low certainty:** this research provides some indication of the likely effect. However, the likelihood that it will be substantially different^†^ is high.\                                                                                                                                                                                                                                                                                                                                     
  **Very low certainty:** this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different^†^ is very high.\                                                                                                                                                                                                                                                                                                              
  ^†^Substantially different = a large enough difference that it might affect a decision.                                                                                                                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------

^a^ In the randomised trial ([Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}), healthcare providers received a one‐hour PowerPoint presentation and handouts on the HPV vaccine, focusing on current evidence‐based HPV vaccine information and strategies designed to assist physicians in discussing HPV vaccination with parents. In addition, parents were mailed a packet that included an educational brochure and DVD video about HPV infection and HPV vaccination as well as a CDC HPV vaccine information statement. Furthermore, health educators conducted an education session with parents about the HPV vaccine via telephone to reinforce the message in the educational materials regarding the need for the vaccine and addressed any vaccination barriers or questions.

In the non‐randomised trial ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}), the intervention included: (1) distribution of HPV vaccination posters and brochures with the risk‐related message to health departments and healthcare providers; (2) two radio public service announcements designed to raise awareness about HPV vaccine for boys among parents of preteen boys; (3) an online continuing medical education training with video demonstrating communication among providers, parents, and preteen boys available to enrolled health providers; (4) one‐page tip sheet for providers to discuss HPV vaccination with parents and boys; and (5) a website with links to credible information sources useful for both parents and providers.

^b^[Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"} (randomised trial).

^c^[Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"} (non‐randomised trial).

^d^ Downgraded by two levels for serious imprecision and serious study limitations (unclear risk of selection bias in the included study) ([Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}).

^e^ Downgraded by two levels for non‐randomised study design ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}).

Background {#CD011895-sec-0030}
==========

Description of the condition {#CD011895-sec-0031}
----------------------------

The World Health Organization (WHO) defines adolescents as people aged between 10 and 19 years ([WHO 2019a](#CD011895-bbs2-0124){ref-type="ref-list"}). Targeting adolescents with relevant vaccines offers three benefits: catch‐up on missed vaccinations, boosting of waning immunity, and primary immunisation with new vaccines ([Brabin 2008](#CD011895-bbs2-0072){ref-type="ref-list"}; [Mackroth 2010](#CD011895-bbs2-0098){ref-type="ref-list"}). Vaccines given during adolescence include, but are not limited to, those against human papillomavirus (HPV), diphtheria, tetanus, pertussis, measles, mumps, rubella, varicella, hepatitis B, poliomyelitis, and meningococcal disease ([Gilkey 2014](#CD011895-bbs2-0087){ref-type="ref-list"}; [Harris 2009](#CD011895-bbs2-0090){ref-type="ref-list"}; [Lee 2005](#CD011895-bbs2-0096){ref-type="ref-list"}; [Mavundza 2019](#CD011895-bbs2-0100){ref-type="ref-list"}; [Piot 2019](#CD011895-bbs2-0109){ref-type="ref-list"}; [SAHM 2013](#CD011895-bbs2-0115){ref-type="ref-list"}; [WHO 2019b](#CD011895-bbs2-0125){ref-type="ref-list"}). Future vaccines against HIV and *Mycobacterium tuberculosis* are likely to target adolescents as the primary population ([Gowda 2012](#CD011895-bbs2-0088){ref-type="ref-list"}; [Zipursky 2010](#CD011895-bbs2-0130){ref-type="ref-list"}).

In many settings, adolescents usually turn to physicians only when they are ill and so there are limited opportunities to inform them that vaccines are important and should be administered ([Cawley 2010](#CD011895-bbs2-0077){ref-type="ref-list"}; [Principi 2013](#CD011895-bbs2-0110){ref-type="ref-list"}). In such instances, adolescents may be more interested in their current health condition than possible benefits of preventing future vaccine‐preventable diseases (VPDs) ([Principi 2013](#CD011895-bbs2-0110){ref-type="ref-list"}). Schools have been used extensively as a delivery platform for vaccinating large numbers of school‐aged children ([Barry 2013](#CD011895-bbs2-0071){ref-type="ref-list"}; [Cawley 2010](#CD011895-bbs2-0077){ref-type="ref-list"}; [Harris 2009](#CD011895-bbs2-0090){ref-type="ref-list"}; [Robbins 2011](#CD011895-bbs2-0113){ref-type="ref-list"}; [Tsu 2009](#CD011895-bbs2-0120){ref-type="ref-list"}). However, school‐based vaccination programmes may not be entirely successful in countries with suboptimal school attendance rates ([Mackroth 2010](#CD011895-bbs2-0098){ref-type="ref-list"}; [Warren 2004](#CD011895-bbs2-0122){ref-type="ref-list"}). For instance, school attendance rates in many low‐ and middle‐income countries (LMICs) are variable due to factors such as geographical location, socioeconomic status, and gender ([Mackroth 2010](#CD011895-bbs2-0098){ref-type="ref-list"}; [Warren 2004](#CD011895-bbs2-0122){ref-type="ref-list"}; [Zipursky 2010](#CD011895-bbs2-0130){ref-type="ref-list"}). Strategies such as mass immunisation campaigns can be used to complement school‐based vaccination programmes in settings with poor school attendance rates ([Clements 2004](#CD011895-bbs2-0078){ref-type="ref-list"}; [Piot 2019](#CD011895-bbs2-0109){ref-type="ref-list"}).

Data on vaccination coverage among adolescents are limited, but coverage is generally low in this group ([Brotherton 2015](#CD011895-bbs2-0074){ref-type="ref-list"}; [Loke 2017](#CD011895-bbs2-0097){ref-type="ref-list"}; [Newman 2018](#CD011895-bbs2-0102){ref-type="ref-list"}). For example, it is estimated that only 6.1% of adolescent girls worldwide completed the full series of HPV vaccination in 2014; with wide variation between LMICs and high‐income countries ([Bruni 2016](#CD011895-bbs2-0075){ref-type="ref-list"}). HPV vaccination coverage was only 1.1% in Asia and 1.2% in Africa, compared to 35.6% in North America and 35.9% in Oceania. Overall, HPV vaccination coverage in 2014 was 33.6% in high‐income countries, compared with only 2.7% in LMICs ([Bruni 2016](#CD011895-bbs2-0075){ref-type="ref-list"}). The most commonly reported barriers to adolescent vaccination include lack of knowledge about vaccines and VPDs; negative attitudes towards vaccination from adolescents, parents, teachers, and healthcare providers; poor vaccine infrastructure; and financial constraints ([Adamu 2019](#CD011895-bbs2-0069){ref-type="ref-list"}; [Gowda 2012](#CD011895-bbs2-0088){ref-type="ref-list"}; [Ngcobo 2018](#CD011895-bbs2-0103){ref-type="ref-list"}; [SAHM 2013](#CD011895-bbs2-0115){ref-type="ref-list"}).

Description of the intervention {#CD011895-sec-0032}
-------------------------------

Interventions to enhance the uptake of vaccines by adolescents may have multiple components, targeting adolescents and their communities, healthcare providers, the health system, or a combination of these ([Wiysonge 2012](#CD011895-bbs2-0129){ref-type="ref-list"}).

### Recipient‐oriented interventions {#CD011895-sec-0033}

Interventions targeting adolescents and their communities (including their parents and teachers) may include education, reminders, incentives, and mandatory vaccination.

*Educational interventions* enable adolescents and their communities to understand the meaning and relevance of vaccination to their health ([Willis 2013](#CD011895-bbs2-0128){ref-type="ref-list"}; [Kaufman 2017](#CD011895-bbs2-0094){ref-type="ref-list"}). Such interventions may be delivered face‐to‐face or via written mail, telephone conversation, audiovisual presentation or drama, printed materials, websites, multi‐media campaigns, or community events ([Willis 2013](#CD011895-bbs2-0128){ref-type="ref-list"}; [Kaufman 2017](#CD011895-bbs2-0094){ref-type="ref-list"}). These types of interventions may be directed at individuals or groups, and may include information about VPDs; the risks and benefits of vaccines; where, how, and when to access vaccine services; who should be vaccinated; or a combination of these ([Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [Williams 2011](#CD011895-bbs2-0127){ref-type="ref-list"}; [Willis 2013](#CD011895-bbs2-0128){ref-type="ref-list"}; [Kaufman 2017](#CD011895-bbs2-0094){ref-type="ref-list"}). Adolescents and communities may receive education about vaccines through prominently displayed posters in waiting rooms, brochures, e‐mails, and website resources ([Stinchfield 2008](#CD011895-bbs2-0118){ref-type="ref-list"}).

*Client reminder interventions* involve reminding members of a target population that vaccinations are due or have been missed. Reminders are delivered using various methods, such as telephone calls, letters, or postcards ([Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"}). The contents of the reminders may include personalised information related to a specific upcoming or missed appointment ([Stinchfield 2008](#CD011895-bbs2-0118){ref-type="ref-list"}; [Willis 2013](#CD011895-bbs2-0128){ref-type="ref-list"}; [Kaufman 2017](#CD011895-bbs2-0094){ref-type="ref-list"}).

*Adolescent or community incentives* involve providing financial or other incentives to motivate people to accept vaccinations ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}). Incentives can be rewards or gifts ([TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}).

*Mandatory vaccination* refers to a law or policy that requires students to show proof of immunisation records prior to school admission with failure to do this resulting in school admission being denied ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}).

### Provider‐oriented interventions {#CD011895-sec-0034}

Provider‐oriented interventions may include reminders, audit and feedback, and education.

*Provider reminder interventions* inform vaccinators that individual clients are due for vaccinations. Reminders may be delivered through client charts, computer, e‐mail, or postal mail, among many others ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}; [Ward 2012](#CD011895-bbs2-0121){ref-type="ref-list"}).

*Audit and feedback for vaccinators* involves retrospectively evaluating the performance of the vaccinators in administering vaccines and providing feedback to them ([Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [Stinchfield 2008](#CD011895-bbs2-0118){ref-type="ref-list"}; [Williams 2011](#CD011895-bbs2-0127){ref-type="ref-list"}). This information is given to providers to motivate them to improve immunisation services.

*Provider education* involves giving information regarding vaccinations to providers to increase their knowledge and to encourage them to adopt positive attitudes towards vaccination. Techniques by which information is delivered can include written materials, videos, lectures, continuing medical education programmes, and computerised software ([TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}; [Ward 2012](#CD011895-bbs2-0121){ref-type="ref-list"}; [Williams 2011](#CD011895-bbs2-0127){ref-type="ref-list"}).

### Health system interventions {#CD011895-sec-0035}

*Outreach programmes* include school‐based immunisation and mass campaigns. School‐based immunisation outreach is intended to improve delivery of vaccinations to school‐going children ([TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}). School‐based interventions usually include vaccination‐related education of students about either provision of vaccinations or referral for vaccinations ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}). Mass campaign programmes target adolescents both in school and out of school ([Clements 2004](#CD011895-bbs2-0078){ref-type="ref-list"}).

*Expanding access in healthcare settings* is used to increase the availability of vaccines in the medical or public health settings in which vaccinations are offered. This can be achieved using several methods such as: increasing or changing the hours during which vaccination services are provided; delivering vaccinations in clinical settings in which they were previously not provided (e.g. emergency departments, inpatient units, or subspeciality clinics); or reducing administrative barriers to obtaining vaccination services within clinics (e.g. developing a \'drop‐in\' clinic or an \'express lane\' vaccination service) ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Stinchfield 2008](#CD011895-bbs2-0118){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}).

*Reducing out‐of‐pocket costs* can be implemented by subsiding the costs of vaccines, paying for vaccinations, providing insurance coverage, or reducing copayments for vaccinations at the point of service ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}).

### Multi‐component interventions {#CD011895-sec-0036}

Multi‐component interventions are approaches that include more than one tactic, with the aim of addressing a variety of barriers to adolescent vaccine uptake. Such interventions could enable communities to be aware of the immunisation services available to them, demonstrate the utility and relevance of these services, provide community members with the knowledge and information base to effectively take advantage of the services, or incorporate a variety of associated provider or health system strategies to improve immunisation uptake ([Briss 2000](#CD011895-bbs2-0073){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [TFCPS 2000](#CD011895-bbs2-0119){ref-type="ref-list"}).

How the intervention might work {#CD011895-sec-0037}
-------------------------------

We have proposed a logic model which suggests how the strategies described in the [Description of the intervention](#CD011895-sec-0032){ref-type="sec"} section may, alone or in combination, influence adolescent vaccination uptake and other outcomes ([Figure 1](#CD011895-fig-0001){ref-type="fig"}).

![Logic framework on interventions for improving uptake of adolescent vaccines. KAP: knowledge, attitudes and practices; VPD: vaccine‐preventable disease.](nCD011895-AFig-FIG01){#CD011895-fig-0001}

Parents, including legal guardians or other people assuming the parental role, are routinely involved in the decision‐making process about vaccine administration to their children ([Kaufman 2018](#CD011895-bbs2-0095){ref-type="ref-list"}). Teachers can also play a crucial role in adolescent vaccination uptake, especially where school‐based vaccination programmes are a popular platform for vaccination of adolescents ([Barry 2013](#CD011895-bbs2-0071){ref-type="ref-list"}; [Tsu 2009](#CD011895-bbs2-0120){ref-type="ref-list"}). In some situations, the final decision on whether an adolescent will be vaccinated or not may be entirely dependent on the parents, as adolescents may not have an independent final decision on whether to get vaccinated ([Barry 2013](#CD011895-bbs2-0071){ref-type="ref-list"}; [WHO 2019a](#CD011895-bbs2-0124){ref-type="ref-list"}). Hence, adequate knowledge and positive attitudes towards vaccination among parents, teachers, and adolescents may improve the uptake of vaccines among adolescents ([Abdullahi 2016](#CD011895-bbs2-0068){ref-type="ref-list"}; [Gowda 2012](#CD011895-bbs2-0088){ref-type="ref-list"}; [Mahomed 2008](#CD011895-bbs2-0099){ref-type="ref-list"}). It is likely that more vaccine‐informed adolescents may be more able to positively guide and influence their parents and peers on vaccinations compared to peers who are less well informed. In addition, adolescents are future parents and investing resources in educating adolescents about vaccination may lead to improved uptake of vaccines by their children ([Barry 2013](#CD011895-bbs2-0071){ref-type="ref-list"}). Therefore, educating adolescents about vaccination may have long‐term positive benefits on vaccine uptake in general ([Principi 2013](#CD011895-bbs2-0110){ref-type="ref-list"}).

Healthcare providers give advice to parents and adolescents on vaccination. The ability of healthcare providers to keep up‐to‐date with knowledge on vaccines is essential, particularly when new vaccines are recommended ([Gowda 2012](#CD011895-bbs2-0088){ref-type="ref-list"}; [Principi 2013](#CD011895-bbs2-0110){ref-type="ref-list"}). Careful and factual advice on vaccination to adolescents and their parents by healthcare providers can result in more willingness to get vaccinated by adolescents. Health system interventions ensure that vaccines are available when adolescent girls and boys, and their communities, demand them ([Kaddar 2013](#CD011895-bbs2-0093){ref-type="ref-list"}).

Why it is important to do this review {#CD011895-sec-0038}
-------------------------------------

Adolescents represent 25% of the global population, but vaccination coverage among them is very low ([Brotherton 2015](#CD011895-bbs2-0074){ref-type="ref-list"}; [Bruni 2016](#CD011895-bbs2-0075){ref-type="ref-list"}; [Loke 2017](#CD011895-bbs2-0097){ref-type="ref-list"}; [Newman 2018](#CD011895-bbs2-0102){ref-type="ref-list"}). There is a knowledge gap around interventions to improve vaccine uptake among adolescents, especially in LMICs. Our review evaluated the evidence on strategies that can be adopted to improve vaccine uptake among adolescents. Such strategies will improve the uptake of current vaccines among adolescents, and may also increase the uptake of future vaccines. In addition, this review could be used to advocate for strengthening existing adolescent vaccination policies and to formulate new policies on the vaccination of adolescents where none currently exist. We are not aware of any previous systematic review that has assessed interventions to improve adolescent immunisation coverage across all country income categories. However, a number of reviews have assessed various strategies to improve immunisation coverage in children or the whole population ([Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"}; [Kaufman 2018](#CD011895-bbs2-0095){ref-type="ref-list"}; [Oyo‐Ita 2016](#CD011895-bbs2-0107){ref-type="ref-list"}; [Saeterdal 2012](#CD011895-bbs2-0114){ref-type="ref-list"}; [Williams 2011](#CD011895-bbs2-0127){ref-type="ref-list"}). These reviews considered general barriers to immunisation and assessed the effects of a variety of interventions. In our review, we used a similar approach among the adolescent population.

Objectives {#CD011895-sec-0039}
==========

To evaluate the effects of interventions to improve vaccine uptake among adolescents.

Methods {#CD011895-sec-0040}
=======

Criteria for considering studies for this review {#CD011895-sec-0041}
------------------------------------------------

### Types of studies {#CD011895-sec-0042}

We included randomised trials, non‐randomised trials, interrupted time series studies, and controlled before‐after studies that met the quality criteria used by Cochrane Effective Practice and Organisation of Care (EPOC) ([EPOC 2019a](#CD011895-bbs2-0083){ref-type="ref-list"}). We included both individually randomised and cluster‐randomised trials. For cluster‐randomised trials, we only included those with at least two intervention and two control clusters. Following the EPOC criteria, we included interrupted time series studies only if outcomes were measured during at least three points before and three points after the intervention. For a controlled before‐after study to be included in the review, it must have included at least two intervention groups and at least two comparable control groups, with simultaneous data collection.

We excluded simple pre--post designs; cluster‐randomised and non‐randomised trials with only one intervention or control site; and controlled before‐after studies without concurrent data collection in intervention and comparison groups in accordance with the EPOC criteria for inclusion of studies in systematic reviews of effects ([EPOC 2019a](#CD011895-bbs2-0083){ref-type="ref-list"}).

### Types of participants {#CD011895-sec-0043}

Girls or boys (or both) aged 10 to 19 years eligible for WHO‐recommended vaccines and their parents or healthcare providers. In the case of studies with interventions directed at mixed populations of children and adolescents or adolescents and adults, we excluded a study if specific data for adolescents were not reported.

### Types of interventions {#CD011895-sec-0044}

#### Intervention {#CD011895-sec-0045}

*Recipient‐oriented interventions* (i.e. interventions targeting adolescents or their communities, or both), for example:interventions to communicate with adolescents or their parents (or both) about adolescent immunisation;financial and non‐financial incentives for adolescents or their parents (or both); andmandatory vaccination: vaccination requirement for high school and university attendance.*Provider‐oriented interventions*, for example:any intervention to reduce missed opportunities for vaccination (e.g. audit and feedback); andhealth education, training, and supportive supervision.*Health system interventions*, for example:interventions to improve the quality of services, such as provision of reliable cold chain systems, provision of transport for vaccination, vaccine stock management;outreach programmes, for example, school‐based immunisation and mass vaccination campaign for out‐of‐school adolescents;expanded services, for example, extended hours for immunisation services;increased immunisation budget; andintegration of immunisation services with other services.*Multi‐component interventions*.

#### Exclusions {#CD011895-sec-0046}

We excluded interventions to remind recipients or providers of immunisation services, as there is already a Cochrane Review on this topic ([Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"}).

#### Comparisons {#CD011895-sec-0047}

Standard immunisation practices in the study setting.Alternative interventions.Similar interventions implemented with different degrees of intensity.

### Types of outcome measures {#CD011895-sec-0048}

#### Primary outcomes {#CD011895-sec-0049}

Adolescent vaccination coverage, that is, the proportion of adolescents who have received the recommended dose(s) of the vaccine(s) studied.

#### Secondary outcomes {#CD011895-sec-0050}

Proportion of adolescents completing the schedule.Equitable uptake of immunisation (as defined by the study authors).Knowledge, attitudes, and beliefs.Adverse effects of the intervention.Cost of the intervention.Incidence of VPDs.

Search methods for identification of studies {#CD011895-sec-0051}
--------------------------------------------

With the assistance of the Cochrane EPOC Information Specialist, we developed search strategies, with no restrictions on language or publication date. The search strategies for the electronic databases incorporated the Cochrane EPOC search strategy for randomised trials, non‐randomised trials, interrupted time series studies, and controlled before‐after studies ([EPOC 2019a](#CD011895-bbs2-0083){ref-type="ref-list"}), and combined selected MeSH and free‐text terms relating to adolescent vaccination uptake literature globally.

### Electronic searches {#CD011895-sec-0052}

We searched the following databases for primary studies:

Cochrane Central Register of Controlled Trials (CENTRAL) 2017, Issue 1; part of the Cochrane Library ([www.cochranelibrary.com](www.cochranelibrary.com); searched 31 October 2018);MEDLINE Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, MEDLINE Daily, and MEDLINE (1946 to 31 October 2018);Embase Ovid (1974 to 31 October 2018);CINAHL EBSCOhost (1981 to 31 October 2018);Africa‐Wide Information EBSCOhost (19th century to 31 October 2018);Global Health Ovid (1973 to 31 October 2018);Scopus, Elsevier (searched 31 October 2018); andScience Citation Index Expanded; Social Sciences Citation Index (1987 to October 2018), and Emerging Sources Citation Index (2015 to October 2018), Web of Science Core Collection, Thompson Reuters (searched 24 April 2017) (for papers citing any of the included studies in the review 31 April 2019).

We searched the following databases for related reviews:

Cochrane Database of Systematic Reviews (CDSR), 2017, Issue 3, part of the Cochrane Library ([www.cochranelibrary.com](www.cochranelibrary.com); searched 31 October 2018);Database of Abstracts of Reviews of Effects (DARE), 2015, Issue 2, part of the Cochrane Library ([www.cochranelibrary.com](www.cochranelibrary.com); searched 31 October 2018);Health Technology Assessment Database (HTA), 2016, Issue 4 (searched 31 October 2018);PDQ‐Evidence (searched 31 October 2018).

In addition, in May 2019, we did a citation search using: Science Citation Index Expanded; Social Sciences Citation Index (from 1987), and Emerging Sources Citation Index (from 2015), Web of Science Core Collection, and Clarivate Analytics.

See [Appendix 1](#CD011895-sec-0144){ref-type="app"} for search strategies used.

### Searching other resources {#CD011895-sec-0053}

#### Grey literature {#CD011895-sec-0054}

We searched the following grey literature (31 October 2018):

WHO ([www.who.int/](www.who.int/));Gavi, the Vaccine Alliance ([www.gavi.org](www.gavi.org));United Nations Children\'s Funds (UNICEF; [www.unicef.org/](www.unicef.org/));PATH Vaccine Resources Library ([www.path.org/](www.path.org/));US Centers for Disease Control and Prevention (CDC; [www.cdc.gov/](www.cdc.gov/));The Communication Initiative Network ([www.comminit.com/](www.comminit.com/));Grey Literature Report ([www.greylit.org](www.greylit.org));OpenGrey ([www.opengrey.eu/](www.opengrey.eu/));Eldis ([www.eldis.org/](www.eldis.org/));Immunization Basics ([www.immunizationbasics.jsi.com](www.immunizationbasics.jsi.com)).

#### Trial registries {#CD011895-sec-0055}

We searched the following trial registries (31 October 2018):

WHO International Clinical Trials Registry Platform (ICTRP; [www.who.int/ictrp/en/](www.who.int/ictrp/en/));ClinicalTrials.gov, US National Institutes of Health (NIH; [clinicaltrials.gov/](clinicaltrials.gov/)).

#### Reference lists {#CD011895-sec-0056}

We searched the reference lists of potentially eligible studies and relevant previous reviews.

Data collection and analysis {#CD011895-sec-0057}
----------------------------

### Selection of studies {#CD011895-sec-0058}

Two review authors (LA and BK) screened titles and abstracts to select potentially eligible studies. One review author (LA) then obtained the full text of potentially eligible studies and two review authors (LA and VN) independently conducted the final study selection for inclusion in the review. We resolved any disagreements regarding the inclusion of studies by discussion or by consulting a third review author (BK and CW). We used a PRISMA flow chart ([Moher 2009](#CD011895-bbs2-0101){ref-type="ref-list"}) to summarise the search and selection of studies for the review ([Figure 2](#CD011895-fig-0002){ref-type="fig"}).

![Study flow diagram.](nCD011895-AFig-FIG02){#CD011895-fig-0002}

### Data extraction and management {#CD011895-sec-0059}

Two review authors (LA and VN) independently extracted data from selected studies using an adapted version of the Cochrane data extraction form. Disagreements on study selection and data extraction were resolved by consensus between the two review authors, failing which a third review author (BK) arbitrated. Prior to use, we piloted the data extraction form on four studies identified randomly from the list of included studies.

The data extraction form included the following items.

Setting of the study (city and country).Type of study: randomised trials, non‐randomised trials, interrupted time series studies, and controlled before‐after studies.Type of participants: adolescents, parents, healthcare providers.Type of interventions: name of intervention, frequency, timing, delivery method, venue of delivery.Type of outcomes measured: vaccine coverage, knowledge, attitudes and beliefs, cost of intervention, adverse effects of the intervention, equity.

When dichotomous outcome data were presented as percentages, we multiplied the percentages by the number of participants in the study arm to obtain the approximate number of events.

### Assessment of risk of bias in included studies {#CD011895-sec-0060}

We applied the Cochrane EPOC \'Risk of bias\' criteria for randomised trials, non‐randomised trials, interrupted time series studies, and controlled before‐after studies, as appropriate ([EPOC 2019b](#CD011895-bbs2-0084){ref-type="ref-list"}). For each included study, we reported our assessment of risk of bias (low, high, or unclear risk) for each domain, together with a descriptive summary of the information that influenced our judgement. Any study that was assigned a high risk of bias for allocation concealment, blinding of outcome assessment, completeness of outcome data, or a combination of these was considered to have a high risk of bias. Studies with low risk of bias for all three domains were considered to have a low risk of bias, and all other studies were considered to have an unclear risk of bias. Two review authors (LA and VN) applied the criteria independently and a third review author (CW) arbitrated any disagreements.

### Measures of treatment effect {#CD011895-sec-0061}

We used raw dichotomous data reported in each study to express the study\'s result as a risk ratio (RR) with its corresponding 95% confidence interval (CI). However, one study reported adjusted odds ratios (ORs) and we calculated the natural logarithm of the OR and its standard error for each outcome in this study. We then expressed the intervention effect for each outcome in this study as an OR with its 95% CI using inverse variance. We grouped studies with broadly similar types of participants, interventions, study designs, and outcomes to get feasible results for an overall estimate of effect. See [Appendix 2](#CD011895-sec-0145){ref-type="app"} for measures of effect specified in the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), but not used in the review.

### Unit of analysis issues {#CD011895-sec-0062}

We did not encounter unit‐of‐analysis issues in this review. Two included studies were cluster‐randomised trials based on matched pairs of clusters ([Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}). We did not reanalyse these data as matching cannot be taken into account in reanalyses in such studies unless the raw data are available. However, the studies conducted appropriate analyses of the data, and we provided the results as reported in the studies. See [Appendix 2](#CD011895-sec-0145){ref-type="app"} for methods specified in the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), but not used in the review.

### Dealing with missing data {#CD011895-sec-0063}

For the current version of the review, we did not experience any missing data thus we did not contact the primary study authors for missing data. In [Appendix 2](#CD011895-sec-0145){ref-type="app"}, we indicated methods specified in the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), but not used in the review.

### Assessment of heterogeneity {#CD011895-sec-0064}

We reviewed heterogeneity in the type of intervention, type of setting, study design, and risk of bias of included studies in order to make an assessment of the extent to which the included studies were similar to each other. We examined the levels of heterogeneity between study results using the Chi² test of homogeneity (with significance defined at the alpha level of 10%). We quantified any statistical heterogeneity between study results using the I² statistic. We regarded heterogeneity as substantial if the I² was greater than 50% ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}).

### Assessment of reporting biases {#CD011895-sec-0065}

Test for asymmetry with a funnel plot was not feasible because the number of included studies for each meta‐analysis was less that the recommended 10 studies. We have archived methods for assessing reporting biases in [Appendix 2](#CD011895-sec-0145){ref-type="app"} , for use in updates of this review.

### Data synthesis {#CD011895-sec-0066}

We pooled data from studies of similar study designs, similar interventions, similar participants, and similar outcomes in a meta‐analysis using the random‐effects model if there was no significant statistical heterogeneity, methodological difference, or high risk of bias. For outcomes with substantial variation between studies in the reported interventions, participants, study designs, and outcome measures, we did not pool the results but summarised the findings in a narrative format. Overall, we interpreted the study findings by taking into account the methodological quality of the studies and the strength of the evidence. For each observed effect, we explicitly stated the strength of evidence and drew conclusions. See [Appendix 2](#CD011895-sec-0145){ref-type="app"} for data synthesis methods specified in the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), but not used in the review.

#### \'Summary of findings\' tables {#CD011895-sec-0067}

We created \'Summary of findings\' tables for the main intervention comparisons and included the primary outcome: vaccination coverage. We used the GRADE approach to assess the certainty of evidence at outcome level ([Guyatt 2008](#CD011895-bbs2-0089){ref-type="ref-list"}). Two review authors (LA and CW) independently assessed the certainty of the evidence (high, moderate, low, and very low) using the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias). We used methods and recommendations described in Section 8.5 and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}), and the EPOC worksheets ([EPOC 2019c](#CD011895-bbs2-0085){ref-type="ref-list"}), and used GRADEpro software. We resolved disagreements on certainty ratings by discussion and provided justification for decisions to downgrade the ratings using footnotes in the table and made comments to aid readers\' understanding of the review where necessary. We used plain language statements to report these findings in the review ([EPOC 2019d](#CD011895-bbs2-0086){ref-type="ref-list"}; [Santesso 2019](#CD011895-bbs2-0116){ref-type="ref-list"}).

### Subgroup analysis and investigation of heterogeneity {#CD011895-sec-0068}

We did not have sufficient data to conduct planned subgroup analyses ([Appendix 2](#CD011895-sec-0145){ref-type="app"}). However, we conducted a posthoc subgroup analysis exploring the effect of variations in the intervention ([Analysis 6.1](#CD011895-fig-0010){ref-type="fig"}; [Analysis 6.2](#CD011895-fig-0011){ref-type="fig"}; [Analysis 6.3](#CD011895-fig-0012){ref-type="fig"}; [Analysis 6.4](#CD011895-fig-0013){ref-type="fig"}) or comparison ([Analysis 5.1](#CD011895-fig-0009){ref-type="fig"}) groups on vaccination coverage. We used the Chi² test for subgroup differences to test for subgroup interactions.

### Sensitivity analysis {#CD011895-sec-0069}

We planned to perform sensitivity analyses based on unit of analysis errors, risk of bias, and missing data ([Appendix 2](#CD011895-sec-0145){ref-type="app"}). However, available data were insufficient to perform these analyses.

Results {#CD011895-sec-0070}
=======

Description of studies {#CD011895-sec-0071}
----------------------

### Results of the search {#CD011895-sec-0072}

We identified 29,103 records from the electronic databases and other sources. After excluding 3476 duplicates, we screened 25,627 records, and found that 25,560 records were not relevant to our review question. We reviewed the remaining 67 potentially eligible full‐text articles for inclusion and excluded 48 of them for the reasons given in the [Characteristics of excluded studies](#CD011895-sec-0154){ref-type="sec"} table.

Sixteen studies met the inclusion criteria and were included in the review ([Table 11](#CD011895-tbl-0011){ref-type="table"}). Two studies are awaiting classification ([Dempsey 2018](#CD011895-bbs2-0065){ref-type="ref-list"}; [Esposito 2018](#CD011895-bbs2-0066){ref-type="ref-list"}; [Characteristics of studies awaiting classification](#CD011895-sec-0155){ref-type="sec"} table), and one study is ongoing ([Skinner 2015](#CD011895-bbs2-0067){ref-type="ref-list"}; [Characteristics of ongoing studies](#CD011895-sec-0156){ref-type="sec"} table). The search process and selection of studies is presented in [Figure 2](#CD011895-fig-0002){ref-type="fig"}.

###### Summary of included studies

  --------------------------------------------------------------- ------------------------------- ------------- --------------------------------- ---------------------------------------------- ----------------------------- ------------------------------ ---------------------------
  **Study ID**                                                    **Study design**                **Country**   **Participants**                  **Intervention**                               **Comparison**                **Duration of intervention**   **Vaccine target**
  [Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}          Non‐randomised trial            USA           Parents and health providers      Multi‐component providers and parents          Usual practice                3 months                       HPV
  [Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}     Randomised trial                USA           Adolescents                       Health education                               Usual practice                30 minutes                     HPV
  [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}           Controlled before‐after study   USA           Health provider                   Provider education with performance feedback   Usual practice                1 month                        HPV
  [Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}        Randomised trial                USA           Parents                           Health education                               Usual practice                2 months                       Tdap, MCV, HPV, Influenza
  [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}       Cluster‐randomised trial        Sweden        Adolescents                       Health education                               Usual practice                30 minutes                     HPV
  [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}       Randomised trial                UK            Adolescents                       Financial incentives                           Usual practice                6 months                       HPV
  [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}        Randomised trial                USA           Parents and health providers      Multi‐component providers and parents          Usual practice                ---                            HPV
  [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}        Cluster‐randomised trial        USA           Adolescent and health providers   Multi‐component provider intervention          Usual practice                1 months                       HPV
  [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}        Randomised trial                USA           Parents                           Health education                               Usual practice                1 hour                         HPV
  [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}        Randomised trial                USA           Adolescents and caregivers        Health education plus financial incentives     Usual practice                1 hour                         HepB
  [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}        Randomised trial                Australia     Adolescents                       Complex health education                       Simplified health education   1 hour                         HepB
  [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}         Non‐randomised trial            USA           Adolescents                       Health education                               Usual practice                3 months                       HPV
  [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}       Randomised trial                USA           Health providers                  Provider prompts                               Usual practice                2 months                       Tdap, MCV, HPV, Influenza
  [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}         Non‐randomised trial            USA           Adolescent                        Mandatory school entry vaccination             Usual practice                ---                            HepB, Td, and MMR
  [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}          Cluster‐randomised trial        USA           Parents                           Health education                               Usual practice                30--40 minutes                 HPV
  [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}   Cluster‐randomised trial        Tanzania      Adolescents                       Class‐based vaccination                        Age‐based vaccination         12 months                      HPV
  --------------------------------------------------------------- ------------------------------- ------------- --------------------------------- ---------------------------------------------- ----------------------------- ------------------------------ ---------------------------

HepB: hepatitis B virus; HPV: human papillomavirus; MCV: meningococcal conjugate vaccine; MMR: measles--mumps--rubella; Td: tetanus--diphtheria; Tdap: tetanus--diphtheria--acellular--pertussis.

### Included studies {#CD011895-sec-0073}

#### Study design and setting {#CD011895-sec-0074}

Sixteen studies met the inclusion criteria. Eight studies were randomised trials with individuals as the unit of randomisation ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}); four studies were cluster‐randomised trials that used health facilities or schools as the unit of randomisation ([Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}); three studies were non‐randomised trials with at least two intervention and two control arms ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}); and one study was a controlled before‐after study with two intervention and two control arms ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}).

Twelve studies were conducted in the USA ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}); one study was conducted in Australia ([Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}); one study was conducted in Sweden ([Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}); one study was conducted in the UK ([Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}); and one study was conducted in Tanzania ([Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}).

#### Participants {#CD011895-sec-0075}

Two studies enrolled girls only ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}), five studies enrolled boys and girls ([Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}), three studies enrolled parents ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), and two studies enrolled healthcare providers ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}).

Four studies enrolled mixed participants, comprising of adolescents and parents ([Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}), adolescents and healthcare providers ([Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}), and parents and healthcare providers ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}). The healthcare providers included physicians, nurses, and physician assistants.

#### Interventions and comparisons {#CD011895-sec-0076}

We present a summary of the interventions and comparisons used in the included studies in [Table 11](#CD011895-tbl-0011){ref-type="table"} and a detailed description in the [Characteristics of included studies](#CD011895-sec-0153){ref-type="sec"} table.

##### Recipient‐oriented interventions {#CD011895-sec-0077}

The recipient‐oriented intervention studies compared the following to usual care: health education ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), financial incentives ([Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}), health education and financial incentives ([Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}), and a school entry law mandating vaccination ([Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}). The seventh health education study compared a multi‐component intervention to simplified information leaflets ([Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}).

In six health education studies, participants in the intervention arm received structured 30 to 40 minute ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), one hour ([Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}), or two to three day ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}) interactive education on the target disease, vaccine recommendations, vaccine schedule, vaccine efficacy, and vaccine safety. Participants in the comparison \'usual care\' arm received group general health education or education on the prevention of a specific non‐vaccine‐related condition. In the seventh study, participants in the education arm received a complex multi‐component intervention that included a resource fact sheet and assessment; an information video and questions designed to engage the adolescent audience; small group discussions; and an activity to locate resource information on the Internet. However, both the intervention and comparison arms received information brochures consisting of one‐page folded coloured leaflets, outlining in simple terms the risks of the target disease and the benefits and adverse effects of vaccination ([Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}).

##### Provider‐oriented interventions {#CD011895-sec-0078}

The provider‐oriented intervention studies assessed provider prompts ([Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}), provider education with performance feedback ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}), and a multi‐faceted intervention ([Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}), compared to usual care.

##### Health system intervention {#CD011895-sec-0079}

One study compared a class‐based vaccination strategy to an age‐based strategy ([Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}).

##### Multi‐component interventions {#CD011895-sec-0080}

Two studies assessed multi‐faceted interventions aimed at both recipients and providers of vaccination services compared to usual care ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}).

#### Outcomes {#CD011895-sec-0081}

Fifteen studies reported data on our primary outcome, vaccination coverage. Eleven studies evaluated completion of the HPV vaccination schedule ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}). Three studies assessed uptake of vaccines against hepatitis B virus ([Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}). One study examined uptake of tetanus--diphtheria (Td) and measles--mumps--rubella (MMR) vaccines ([Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}). Finally, two studies reported data on uptake of tetanus--diphtheria--acellular--pertussis (Tdap), meningococcal conjugate, HPV, and influenza vaccines ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}).

Other predefined outcome measures reported by the included studies were:

knowledge, attitudes, and beliefs ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"});cost of the intervention ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}); andadverse effects of the intervention ([Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}).

Predefined outcomes not reported by the included studies were:

incidence of VPDs; andequitable uptake of immunisation.

The following predefined outcome was considered in a posthoc assessment as not relevant to the review: adverse events following immunisation (AEFI). An AEFI is any undesirable medical incident which follows administration of a vaccine, but is not necessarily caused by the vaccination ([WHO 2019c](#CD011895-bbs2-0126){ref-type="ref-list"}). It is thus not a relevant outcome in this review, given that we are assessing interventions to improve vaccination uptake rather than the effects of the vaccine itself.

The studies did not report the lag‐time between delivery of interventions and assessment of outcomes.

### Excluded studies {#CD011895-sec-0082}

We excluded 48 studies for reasons given in the [Characteristics of excluded studies](#CD011895-sec-0154){ref-type="sec"} table. The most common reasons for exclusion were ineligible study designs and ineligible interventions.

Risk of bias in included studies {#CD011895-sec-0083}
--------------------------------

### Allocation {#CD011895-sec-0084}

The risk of selection bias (random sequence generation) was low for nine studies ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), unclear for three studies ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}), and high for four studies ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}).

The risk of selection bias (allocation concealment) was low for seven studies ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}), unclear for six studies ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), and high for three studies ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}).

### Blinding {#CD011895-sec-0085}

For the types of intervention assessed in this review, blinding of participants and personnel was not possible. However, since vaccination coverage is an objective measure, we considered all studies to be at low risk of performance and detection biases.

### Incomplete outcome data {#CD011895-sec-0086}

The risk of attrition bias (incomplete outcome data) was low for 12 studies ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), unclear for one study ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}), and high for two studies ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}).

### Selective reporting {#CD011895-sec-0087}

Selective reporting was categorised as low risk in 12 studies ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}), and unclear in four studies ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}).

### Other potential sources of bias {#CD011895-sec-0088}

None of the studies had evidence of other biases.

#### Summary of risk of bias assessments {#CD011895-sec-0089}

We have summarised the risk of bias assessment in each of the included studies in [Figure 3](#CD011895-fig-0003){ref-type="fig"} and [Figure 4](#CD011895-fig-0004){ref-type="fig"}. Overall, three studies had low risk of bias ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}), nine studies had unclear risk of bias ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}; [Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}; [Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}; [Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}; [Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}; [Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}; [Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}; [Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}), and four studies had high of bias ([Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}; [Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}).

![Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.](nCD011895-AFig-FIG03){#CD011895-fig-0003}

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.](nCD011895-AFig-FIG04){#CD011895-fig-0004}

Effects of interventions {#CD011895-sec-0090}
------------------------

See: [Table 1](#CD011895-tbl-0001){ref-type="table"}; [Table 2](#CD011895-tbl-0002){ref-type="table"}; [Table 3](#CD011895-tbl-0003){ref-type="table"}; [Table 4](#CD011895-tbl-0004){ref-type="table"}; [Table 5](#CD011895-tbl-0005){ref-type="table"}; [Table 6](#CD011895-tbl-0006){ref-type="table"}; [Table 7](#CD011895-tbl-0007){ref-type="table"}; [Table 8](#CD011895-tbl-0008){ref-type="table"}; [Table 9](#CD011895-tbl-0009){ref-type="table"}; [Table 10](#CD011895-tbl-0010){ref-type="table"}

We present a summary of the effects of the interventions in [Table 12](#CD011895-tbl-0012){ref-type="table"}. In this table we report the direction of the results and the certainty of the evidence for both primary and secondary outcomes.

###### Intervention‐outcome matrix

  ------------------------------------------------------------------------- -------------------------- ------------ ------------------ --------------- ------------- --------------------- ---------- ----------------------------------
  **Intervention**                                                          **Vaccination coverage**   **Equity**   **Knowledge**      **Attitudes**   **Beliefs**   **Adverse effects**   **Cost**   **Vaccine‐preventable diseases**
  **Recipient‐oriented interventions**                                                                                                                                                                
  1 Health education vs usual practice                                      ✔㊉㊉㊉㊉^1^               NR           ✔㊉㊉㊀㊀^2^       NR              NR            NG                    NR         NR
  2\. Complex vs simplified health education                                **Ø**㊉㊉㊉㊀^3^           NR           ✔㊉㊉㊀㊀^3^       NR              NR            NR                    NR         NR
  3\. Financial incentives vs usual practice                                ✔㊉㊉㊀㊀^4^               NR           NR                 NR              NR            NR                    NR         NR
  4\. Health education plus financial incentives vs usual practice          **?**㊉㊀㊀㊀^5^           NR           **?**㊉㊀㊀㊀^5^   NR              NR            NR                    NR         NR
  5\. Mandatory vaccination vs usual practice                               ✔㊉㊉㊉㊀^6^               NR           NR                 NR              NR            NR                    NR         NR
  **Provider‐oriented interventions**                                                                                                                                                                 
  6\. Provider prompts vs usual practice                                    ✔㊉㊉㊉㊀^7^               NR           NR                 NR              NR            NR                    NR         NR
  7\. Provider education plus performance feedback vs usual practice        ✔㊉㊉㊀㊀^8^               NR           NR                 NR              NR            NR                    NG         NR
  **Health system interventions**                                                                                                                                                                     
  8\. Class‐based vs age‐based HPV vaccination in schools                   ✔㊉㊉㊉㊀^9^               NR           NR                 NR              NR            NR                    NG         NR
  **Multi‐component interventions**                                                                                                                                                                   
  9\. Multi‐component provider intervention vs usual practice               ✔㊉㊉㊀㊀^10^              NR           NR                 NR              NR            NR                    NR         NR
  10\. Multi‐component provider and parent intervention vs usual practice   ✔㊉㊉㊀㊀^11^              NR           ✔㊉㊉㊀㊀^12^      NR              NR            NR                    NR         NR
  ------------------------------------------------------------------------- -------------------------- ------------ ------------------ --------------- ------------- --------------------- ---------- ----------------------------------

✔ = a desirable effect

**Ø** = little or no effect

**?** = uncertain effect

**x** = undesirable effect

vs = Compared to

NR = not reported

NG = outcome not graded

^1^[Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"} (randomised trial), [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"} (cluster‐randomised trial), and [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"} (cluster‐randomised trial).

^2^[Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"} (randomised trial).

^3^[Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"} (randomised trial).

^4^[Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"} (randomised trial).

^5^[Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"} (randomised trial).

^6^[Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"} (non‐randomised trial).

^7^[Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"} (randomised trial).

^8^[Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"} (controlled before‐after study).

^9^[Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"} (cluster‐randomised trial).

^10^[Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"} (cluster‐randomised trial).

^11^[Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"} (randomised trial) and [Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"} (non‐randomised trial).

^12^[Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"} (randomised trial)

**⊕⊕⊕⊕ = High‐certainty evidence**

Definition: this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different is low.

Implications: this research provides a very good basis for making a decision about whether to implement the intervention. Impact evaluation and monitoring of the impact are unlikely to be needed if it is implemented.

**⊕⊕⊕⊖ = Moderate‐certainty evidence**

Definition: this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different is moderate.

Implications: this evidence provides a good basis for making a decision about whether to implement the intervention. Monitoring of the impact is likely to be needed and impact evaluation may be warranted if it is implemented.

**⊕⊕⊖⊖ = Low‐certainty evidence**

Definition: this research provides some indication of the likely effect. However, the likelihood that it will be substantially different is high.

Implications: this evidence provides some basis for making a decision about whether to implement the intervention. Impact evaluation is likely to be warranted if it is implemented.

**⊕⊖⊖⊖ = Very low certainty evidence**

Definition: this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different is very high.

Implications: this evidence does not provide a good basis for making a decision about whether to implement the intervention. Impact evaluation is very likely to be warranted if it is implemented.

### Recipient‐oriented interventions {#CD011895-sec-0091}

#### Comparison 1: health education compared to usual practice {#CD011895-sec-0092}

##### 1.1. Vaccination coverage {#CD011895-sec-0093}

Three randomised trials ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}) and one non‐randomised trial ([Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}) reported vaccination coverage. A meta‐analysis of the randomised trials showed that health education improves HPV vaccination uptake compared to usual practice (RR 1.43, 95% CI 1.16 to 1.76; I² = 0%; high‐certainty evidence; 1054 participants). The non‐randomised study had similar findings, suggesting that health education may improve HPV vaccination uptake compared to usual practice (RR 1.84, 95% CI 1.34 to 2.54; low‐certainty evidence; 2822 participants)([Analysis 1.1](#CD011895-fig-0005){ref-type="fig"}; [Table 1](#CD011895-tbl-0001){ref-type="table"}).

##### 1.2. Secondary outcomes {#CD011895-sec-0094}

###### Knowledge, attitude, and beliefs {#CD011895-sec-0095}

One randomised trial suggested that health education may improve knowledge of vaccines (HPV, meningococcal conjugate, Tdap, and Influenza) and corresponding VPDs compared to usual practice ([Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}). We downgraded the certainty of the evidence to low because of serious study limitations (high risk of bias) and serious indirectness (given that this finding is based on one study from one setting).

###### Adverse effects of the intervention {#CD011895-sec-0096}

One study reported that health education did not have any adverse events in relation to usual practice ([Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}). The remaining studies did not provide any information on adverse effects.

#### Comparison 2: complex health education programme compared to simplified health education {#CD011895-sec-0097}

##### 2.1. Vaccination coverage {#CD011895-sec-0098}

One large randomised trial ([Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}) suggested that a multi‐component health education intervention probably results in little or no difference in the uptake of three doses of the hepatitis B vaccine compared to simplified information leaflets (RR 0.98, 95% CI 0.96 to 0.99; 17,411 participants; [Analysis 2.1](#CD011895-fig-0006){ref-type="fig"}). We judged the certainty of the evidence as moderate because of serious study limitations, as the included study had an unclear risk of bias ([Table 2](#CD011895-tbl-0002){ref-type="table"}).

##### 2.2. Secondary outcomes {#CD011895-sec-0099}

###### Knowledge, attitude, and beliefs {#CD011895-sec-0100}

The randomised trial showed that multi‐component health education may improve knowledge of the targeted vaccine and disease compared to simplified information leaflets ([Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}). We downgraded the certainty of evidence to moderate because of serious study limitations (unclear risk of bias) and serious indirectness (given that this finding is based on one study from one setting).

#### Comparison 3: financial incentives compared to usual practice {#CD011895-sec-0101}

##### 3.1. Vaccination coverage {#CD011895-sec-0102}

One randomised trial ([Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}) found that financial incentives may improve uptake of the first dose of the HPV vaccine compared to usual practice (RR 1.45, 95% CI 1.05 to 1.99; 500 participants; [Analysis 3.1](#CD011895-fig-0007){ref-type="fig"}). We judged the certainty of the evidence as low, because of concerns regarding study limitations (unclear risk of bias) and imprecision of the effect ([Table 3](#CD011895-tbl-0003){ref-type="table"}).

##### 3.2. Secondary outcomes {#CD011895-sec-0103}

None of the included studies reported relevant secondary outcomes for this comparison.

#### Comparison 4: health education plus financial incentives compared to usual practice {#CD011895-sec-0104}

##### 4.1. Vaccination coverage {#CD011895-sec-0105}

From the findings of one small randomised trial ([Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}), we are uncertain about the effects of combining health education and financial incentives on the completion of three doses of the hepatitis B vaccine, compared to usual practice (RR 1.38, 95% CI 0.96 to 2.00; 104 participants; [Analysis 4.1](#CD011895-fig-0008){ref-type="fig"}). We judged the certainty of the evidence as very low because of concerns regarding risk of bias in the included study, very serious imprecision of the findings, and very serious indirectness (given that this finding is based on one small study from one setting) ([Table 4](#CD011895-tbl-0004){ref-type="table"}).

##### 4.2. Secondary outcomes {#CD011895-sec-0106}

###### Knowledge, attitude, and beliefs {#CD011895-sec-0107}

One study ([Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}) assessed this outcome. We are uncertain about the effects of health education plus financial incentives on vaccine knowledge compared to usual practice because the certainty of the evidence was very low. We judged the certainty of the evidence as very low because of serious study limitations and very serious indirectness.

#### Comparison 5: mandatory vaccination compared to usual practice {#CD011895-sec-0108}

##### 5.1. Vaccination coverage {#CD011895-sec-0109}

[Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"} assessed the effects of mandating hepatitis B vaccination by law for elementary school entry in the state of Missouri in the USA. This non‐randomised trial compared students in the ninth grade (affected by the hepatitis B law) and 12th grade (not affected by the law) in the state and showed that making vaccinations mandatory probably leads to substantial improvements in vaccination uptake (RR 2.94, 95% CI 2.66 to 3.25; 2642 participants; [Analysis 5.1](#CD011895-fig-0009){ref-type="fig"}).

In addition, the study compared the ninth grade in Missouri (affected by the mandatory hepatitis B vaccination law) to the ninth grade in the state of Kansas (not affected by the law) and confirmed that mandating vaccination probably leads to a large increase in the uptake of hepatitis B vaccine (RR 3.92, 95% CI 3.65 to 4.20; 6462 participants; [Analysis 5.1](#CD011895-fig-0009){ref-type="fig"}). This was a well conducted non‐randomised study and, for both outcome assessments, we upgraded the certainty of the evidence to moderate because of very large intervention effects ([Table 5](#CD011895-tbl-0005){ref-type="table"}).

##### 5.2. Secondary outcomes {#CD011895-sec-0110}

The study reported no relevant secondary outcomes.

### Provider‐oriented interventions {#CD011895-sec-0111}

#### Comparison 6: provider prompts compared to usual practice {#CD011895-sec-0112}

##### 6.1. Vaccination coverage {#CD011895-sec-0113}

[Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"} assessed the impact of provider prompts compared to usual practice on the uptake of various recommended adolescent vaccines through two parallel randomised trials: one in a national network of paediatric clinics, covering 36 states in the USA, and one in a local network of primary care practices, based in one county in New York state in the USA.

In the national network of paediatric clinics, provider prompts probably made little or no difference to the uptake of three doses of HPV (adjusted OR 1.13 95% CI 0.68 to 1.88; 437 participants), Tdap (adjusted OR 1.16, 95% CI 0.68 to 1.99; 1746 participants), meningococcal conjugate (adjusted OR 1.08, 95% CI 0.82 to 1.41; 1752 participants), and seasonal influenza (adjusted OR 0.89, 95% CI 0.69 to 1.16; 878 participants) vaccines. These adjusted odds ratios were based on a multilevel mixed‐effect logistic regression model with covariates for pair assignment, study time period, group assignment, and an interaction between time and group assignment.

In the local network of primary care practices, provider prompts probably made little or no difference to the uptake of three doses of HPV (adjusted OR 0.93, 95% CI 0.64 to 1.34; 422 participants), Tdap (adjusted OR 1.44, 95% CI 0.82 to 2.56; 1550 participants), meningococcal conjugate (adjusted OR 1.15, 95% CI 0.64 to 2.05; 1467 participants), and seasonal influenza (adjusted OR 0.93, 95% CI 0.69 to 1.25; 561 participants) vaccines. The odds ratios were adjusted as for the national network results above.

Pooling the data from the two networks, this randomised trial shows that provider prompts probably make little or no difference to the uptake of three doses of HPV (OR 0.99, 95% CI 0.55 to 1.81; 859 participants; [Analysis 6.1](#CD011895-fig-0010){ref-type="fig"}), Tdap (OR 1.28, 95% CI 0.59 to 2.80; 3296 participants; [Analysis 6.2](#CD011895-fig-0011){ref-type="fig"}), meningococcal conjugate (OR 1.09, 95% CI 0.67 to 1.79; 3219 participants; [Analysis 6.3](#CD011895-fig-0012){ref-type="fig"}), and seasonal influenza (OR 0.91, 95% CI 0.61 to 1.34; 1439 participants; [Analysis 6.4](#CD011895-fig-0013){ref-type="fig"}) vaccines.

We judged the certainty of the evidence as moderate because of concerns regarding imprecision of findings ([Table 6](#CD011895-tbl-0006){ref-type="table"}).

##### 6.2. Secondary outcomes {#CD011895-sec-0114}

The study reported no relevant secondary outcomes.

#### Comparison 7: provider education with performance feedback compared to usual practice {#CD011895-sec-0115}

##### 7.1. Vaccination coverage {#CD011895-sec-0116}

One controlled before‐after study looked at the effects of education and performance feedback on the uptake of HPV vaccination ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}). Provider education with performance feedback may increase the proportion of adolescents who are offered and accept HPV vaccination by clinicians, compared to usual practice. Compared to adolescents visiting non‐participating clinicians (in the usual practice group), the adolescents visiting clinicians in the intervention group were more likely to receive the first dose of HPV during preventive visits (5.7 percentage points increase) and during acute visits (0.7 percentage points for the first and 5.6 percentage points for the second doses of HPV)(227 clinicians and more than 200,000 children). We judged the certainty of the evidence as low because this is a non‐randomised study ([Table 7](#CD011895-tbl-0007){ref-type="table"}).

##### 7.2. Secondary outcomes {#CD011895-sec-0117}

###### Cost {#CD011895-sec-0118}

[Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"} evaluated the costs required to implement the education and performance feedback programme. The authors calculated the total cost of each of the following components: creation of the performance feedback reports; time spent on creating and delivering the educational content; and time spent by participating providers on group calls, reviewing data, and planning/implementing practice change. The estimated total cost of the intervention was USD 17,887 (USD 662 per participant), of which USD 17,064 was for participant time spent on the programmes ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}).

### Health system interventions {#CD011895-sec-0119}

#### Comparison 8: class‐based compared to age‐based HPV vaccination in schools {#CD011895-sec-0120}

##### 8.1. Vaccination coverage {#CD011895-sec-0121}

[Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"} assessed the effect of two HPV vaccine delivery strategies in a cluster randomised trial and showed that a class‐based delivery tactic probably leads to slightly higher HPV vaccine uptake than an age‐based delivery strategy (RR 1.09, 95% CI 1.06 to 1.13; 1 study, 5537 participants; [Analysis 7.1](#CD011895-fig-0014){ref-type="fig"}). We judged the certainty of the evidence as moderate because of serious indirectness, given that this finding is based on one study from one setting ([Table 8](#CD011895-tbl-0008){ref-type="table"}).

##### 8.2. Secondary outcomes {#CD011895-sec-0122}

###### Cost {#CD011895-sec-0123}

[Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"} collected data on the costs of class‐based versus age‐based delivery of the HPV vaccine in Tanzania and found the class‐based vaccination strategy to be less expensive. In urban schools, the cost was USD 52 per girl vaccinated in a class‐based strategy compared to USD 87 for the age‐based delivery system. In rural schools, the cost was USD 67 per girl vaccinated in a class‐based strategy compared to USD 98 for the age‐based delivery system.

### *Multi‐component* interventions {#CD011895-sec-0124}

#### Comparison 9: multi‐component provider intervention compared to usual practice {#CD011895-sec-0125}

##### 9.1. Vaccination coverage {#CD011895-sec-0126}

[Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"} (cluster randomised trial) assessed the effects of a four‐component provider intervention package (education session, repeated contacts, individualised feedback, and incentives) and found that the intervention probably improves HPV vaccination coverage compared to usual practice. Girls in the intervention group are probably more likely to receive their next HPV vaccine dose than those in the control group (odds ratio 1.6, 95% CI 1.1 to 2.2; 5786 participants). The effects are probably larger for boys (odds ratio 25.00, 95% CI 15.00 to 40.00; 7332 participants), and this may be because publicly funded HPV vaccination for boys became available during the study. We judged the certainty of the evidence as moderate because of serious indirectness, given that this finding is based on one study from one setting ([Table 9](#CD011895-tbl-0009){ref-type="table"}).

##### 9.2. Secondary outcomes {#CD011895-sec-0127}

The study reported no relevant secondary outcomes.

#### Comparison 10: multi‐component provider and parent intervention compared to usual practice {#CD011895-sec-0128}

##### 10.1. Vaccination coverage {#CD011895-sec-0129}

One non‐randomised trial showed that a social marketing intervention directed to parents and providers may improve HPV vaccination uptake compared to usual practice (RR 1.41, 95% CI 1.25 to 1.59; 25,869 participants; [Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}). The intervention included: distribution of HPV vaccination pamphlets to healthcare providers; radio messages directed at adolescents and their parents to raise awareness about HPV vaccination; an online continuing medical education training on HPV vaccination for health providers; simplified information sheet for adolescents and parents; and a website with links to credible information sources for parents and providers.

A very small randomised trial ([Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}) also suggested that a multi‐component educational intervention directed to both providers and parents may improve HPV vaccination uptake (RR 2.34, 95% CI 0.75 to 7.32; 337 participants). Healthcare providers received a one‐hour presentation and handouts on HPV vaccination, and parents were mailed simplified educational material on HPV vaccination followed by a phone call to emphasise the importance of HPV vaccination.

Overall, the two studies show that using a multi‐faceted provider and parent intervention may improve HPV vaccination uptake compared to usual practice ([Analysis 8.1](#CD011895-fig-0015){ref-type="fig"}). We judged the certainty of the evidence as low because of concerns regarding serious imprecision and serious study limitations (unclear risk of selection bias in the included study) ([Table 10](#CD011895-tbl-0010){ref-type="table"}).

##### 10.2. Secondary outcomes {#CD011895-sec-0130}

###### Knowledge, attitude, and beliefs {#CD011895-sec-0131}

[Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"} reported that a multi‐component educational intervention directed to both providers and parents may increase knowledge about HPV infection and HPV vaccine among providers and parents compared to usual practice. The average number of correct answers about HPV infection and HPV vaccination (out of 10) post‐intervention among parents in the intervention group was 9.4 (standard deviation 1.0), compared to 7.3 (standard deviation 1.9) among parents in the comparison group (P = 0.001). We judged the certainty of the evidence as low because of serious indirectness (given that this finding is based on one study from one setting) and serious study limitations.

Discussion {#CD011895-sec-0132}
==========

Summary of main results {#CD011895-sec-0133}
-----------------------

We found that educating adolescents and their parents about the importance of vaccinations; passing laws stating that adolescents must be vaccinated to go to school; using a multi‐faceted package of interventions for providers of vaccination services, including education, repeated contacts, individualised feedback, and incentives; or using class‐based rather than age‐based approaches for delivering vaccines probably improve adolescent vaccination coverage. Adolescent vaccination coverage may also be improved through targeting parents and healthcare providers with a combination of vaccination education, telephone calls, and radio messages. In addition, providing adolescents and their parents with financial incentives may improve adolescent vaccination coverage. However, reminding healthcare providers to vaccinate adolescents when they open their electronic medical charts, probably makes little or no difference to adolescent vaccination coverage. From the data provided in the studies included in this review, we were uncertain about the costs of the interventions tested and their effects on knowledge and attitudes regarding adolescent vaccination. [Table 12](#CD011895-tbl-0012){ref-type="table"} shows a summary of the effects of the interventions, indicating the certainty of the evidence and gaps in the evidence base.

Overall completeness and applicability of evidence {#CD011895-sec-0134}
--------------------------------------------------

Our systematic review was comprehensive as we included all known types of interventions for improving vaccination coverage (except recipient‐oriented reminders ([Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"})), all vaccines recommended by WHO for boys and girls aged 10 to 19 years ([WHO 2019b](#CD011895-bbs2-0125){ref-type="ref-list"}), and all country settings. However, we identified only 16 eligible studies, mostly conducted in high‐income countries.

There may be multiple barriers and facilitators of vaccine uptake among adolescents, from the logistics of ensuring access and the affordability of vaccination services, to the psychosocial factors that influence vaccination‐seeking behaviours and individual acceptance of vaccination. Therefore, multiple interventions may be required to achieve optimal vaccination coverage among adolescents. This review showed promising findings for a range of interventions including recipient‐oriented education, vaccine mandates, and financial incentives; provider education and a combination of interventions targeting providers alone or together with parents; and tailored school outreach programmes.

The most promising intervention was mandatory vaccination, which increased hepatitis B vaccination coverage more than four‐fold ([Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}). This study was conducted in the US states of Missouri (which had a law mandating hepatitis B vaccination for school entry) and Kansas (which did not have mandatory hepatitis B vaccination at the time of the study). The study authors noted that the vaccination coverage achieved in this study (i.e. 72.8%) did not reach the high coverage levels obtained following a similar vaccination mandate in California. This was probably because, unlike in Missouri, mandatory vaccination in California was stringently enforced through measures such as expulsion of unvaccinated students and inspections to verify that vaccination coverage levels reported by schools were correct. Various countries have mandates for several vaccines ([Omer 2019](#CD011895-bbs2-0106){ref-type="ref-list"}). However, there is considerable variation between and within countries in the implementation of mandatory vaccination; including (but not limited to) variation in what is required of people, the penalties imposed if requirements are not met, and the age groups and populations covered by vaccine mandates; ([Attwell 2019](#CD011895-bbs2-0070){ref-type="ref-list"}; [Omer 2019](#CD011895-bbs2-0106){ref-type="ref-list"}). Therefore, countries considering mandatory vaccination, as part of a multi‐intervention approach to reach optimal immunisation coverage among adolescents, may want to ensure that the process is consultative, involving relevant national stakeholders in its planning, implementation, and monitoring. National immunisation decision makers should bear in mind that mandatory vaccination is unlikely to be effective in settings where healthcare facility obstacles and other access issues are major drivers of sub‐optimal vaccination coverage ([Adamu 2019](#CD011895-bbs2-0069){ref-type="ref-list"}; [Nnaji 2020](#CD011895-bbs2-0104){ref-type="ref-list"}). In addition, the [Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"} study was conducted more than 15 years ago, and it is possible that changes in health systems arrangements and other contextual changes since the time of the study may impact on the applicability of this evidence.

We also found health education to be very effective, leading to a relative increase of 43% in the completion of a three‐dose schedule of HPV vaccination ([Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}; [Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}; [Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}; [Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}). In addition, we found little or no difference in effects between a complex multi‐component health education intervention and simplified information leaflets; suggesting that interventions need to be tailored to local vaccination barriers.

This review has several limitations in relation to the applicability of this evidence. First, 15/16 included studies were conducted in high‐income countries, mainly the USA, in which vaccination services are readily available to adolescent girls and boys. The findings from these studies need to be interpreted with caution when applied to settings with different health system arrangements and access to vaccination services. Second, there was limited information from the studies on the cost‐effectiveness of the interventions tested. Only two studies reported the costs of interventions, including provider education with performance feedback ([Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}) and a health system intervention ([Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}). Therefore, when applying the findings of this review to any setting, local costing should be undertaken, particularly in settings differing from those of the original investigations. Third, the studies included in this review did not report information on equity. It is possible that the implementation of interventions may increase inequity if they are not adapted to populations in remote and under‐served areas in countries or if there is substantial variability in socioeconomic characteristics among populations receiving the interventions. Given these contextual issues, any adolescent vaccination programmes implemented based on our review findings should include a monitoring component to assess the performance of the intervention within the given context.

One study in our review was conducted in a country defined by the World Bank as low‐income or middle‐income ([Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}). The study compared class‐based and age‐based strategies for delivering HPV vaccines among 5532 girls in 134 primary schools in northwest Tanzania (a low‐income country). There was a 9% relative increase in vaccination coverage among eligible girls in schools assigned to a class‐based approach compared to girls in schools using an age‐based strategy. This finding may be relevant to (low‐ or middle‐income) countries that do not have established healthcare programmes for adolescent boys and girls, but have introduced or are contemplating to introduce HPV ([Oberlin 2018](#CD011895-bbs2-0105){ref-type="ref-list"}) and other vaccines for adolescents. School health programmes can have an advantage of integrating various existing health services at the same or a minimal increase in cost ([Robbins 2011](#CD011895-bbs2-0113){ref-type="ref-list"}). In line with our findings, one previous review of school‐based programmes in 17 countries found that such programmes led to substantial increases in HPV vaccination coverage rates ([Paul 2014](#CD011895-bbs2-0108){ref-type="ref-list"}).

Although the effect sizes reported in this review were small to moderate, even relatively small effects for interventions aimed at increasing uptake of adolescent vaccines may be important from a health service perspective, when applied across large populations. Therefore, we believe that this review is an important resource for countries and international organisations in the context of the \"Immunization Agenda 2030\", a global strategy which envisions a \"world where everyone, everywhere, at every age, fully benefits from vaccines for good health and well‐being\" ([WHO 2019](#CD011895-bbs2-0123){ref-type="ref-list"}).

Three quarters of the studies in this review assessed the effects of various interventions on HPV vaccination coverage. Despite a global expansion of HPV vaccination programmes in recent years, HPV vaccination coverage remains sub‐optimal worldwide ([Brotherton 2015](#CD011895-bbs2-0074){ref-type="ref-list"}; [Bruni 2016](#CD011895-bbs2-0075){ref-type="ref-list"}; [Loke 2017](#CD011895-bbs2-0097){ref-type="ref-list"}; [Newman 2018](#CD011895-bbs2-0102){ref-type="ref-list"}). The current review will be supplemented by a Cochrane qualitative evidence synthesis which will explore the factors that influence acceptance of adolescent HPV vaccination ([Cooper 2019](#CD011895-bbs2-0079){ref-type="ref-list"}). The findings may help to explain why some interventions in the current review were more effective than others, and may contribute to the development of more effective and contextualised interventions for improving HPV vaccination uptake among adolescents.

### Certainty of the evidence {#CD011895-sec-0135}

The certainty of the evidence on the effects of included interventions on our primary outcome (adolescent vaccination coverage) varied widely, from high to very low. Among the interventions targeting adolescents and their communities, we judged the certainty of the evidence as high for education ([Table 1](#CD011895-tbl-0001){ref-type="table"}), moderate for multi‐component health education ([Table 2](#CD011895-tbl-0002){ref-type="table"}) and legislation mandating vaccination ([Table 5](#CD011895-tbl-0005){ref-type="table"}), low for financial incentives ([Table 3](#CD011895-tbl-0003){ref-type="table"}), and very low for a combination of health education and financial incentives ([Table 4](#CD011895-tbl-0004){ref-type="table"}). Regarding provider‐oriented interventions, we assessed the certainty as moderate for provider prompts ([Table 6](#CD011895-tbl-0006){ref-type="table"}) and multi‐component performance improvement continuing medical education intervention ([Table 9](#CD011895-tbl-0009){ref-type="table"}) and low for provider education with performance feedback ([Table 7](#CD011895-tbl-0007){ref-type="table"}). For the combination of recipient and provider interventions, we assessed the certainty of evidence as moderate ([Table 10](#CD011895-tbl-0010){ref-type="table"}). On health system interventions, we judged the certainty of the evidence as moderate for class‐based compared to age‐based delivery of vaccines to adolescents ([Table 8](#CD011895-tbl-0008){ref-type="table"}). Our main concerns with the evidence related to study limitations (risk of bias; [Figure 3](#CD011895-fig-0003){ref-type="fig"}; [Figure 4](#CD011895-fig-0004){ref-type="fig"}), indirectness (for findings based on single studies from one setting), and imprecision.

Potential biases in the review process {#CD011895-sec-0136}
--------------------------------------

We minimised potential biases in the review process by adhering to Cochrane guidelines ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}). We conducted comprehensive searches without limiting the searches to a specific language. Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included study. The eligible cluster‐randomised trials reported that they adjusted for cluster effects. However, there was some level of subjectivity in the determination of concerns that were serious enough to require rating down the evidence; and it is possible that other authors would have arrived at slightly different levels of certainty of evidence.

The searches for the main databases were done in October 2018. It is possible that some relevant studies published after the last search date have not been included in the review and the review authors acknowledge this limitation, However, we do not think that this limitation has an impact on the reliability of the main findings and conclusions of the review.

Agreements and disagreements with other studies or reviews {#CD011895-sec-0137}
----------------------------------------------------------

Few recent systematic reviews have assessed the effectiveness of interventions for improving adolescent immunisation coverage ([Das 2016](#CD011895-bbs2-0080){ref-type="ref-list"}; [Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"}; [Smulian 2016](#CD011895-bbs2-0117){ref-type="ref-list"}). Das and colleagues searched three databases for studies published up to December 2014 and included 23 studies on the effectiveness of interventions to improve vaccination coverage among adolescents. The authors reported that evidence of moderate certainty from 13 studies suggested that mandatory vaccination in schools, reminders, and national permissive recommendation increased vaccination coverage in adolescents ([Das 2016](#CD011895-bbs2-0080){ref-type="ref-list"}). Smulian and colleagues searched five databases and included 34 intervention studies published from June 2006 to May 2015. The authors reported that many types of intervention strategies (targeting recipients, providers, and the health system) led to increases in HPV vaccination coverage in different settings ([Smulian 2016](#CD011895-bbs2-0117){ref-type="ref-list"}). The [Das 2016](#CD011895-bbs2-0080){ref-type="ref-list"} and [Smulian 2016](#CD011895-bbs2-0117){ref-type="ref-list"} reviews had some overlap with our review in terms of included studies, but many studies included in the two reviews do not meet the EPOC criteria for inclusion of studies in systematic reviews of effects ([EPOC 2019a](#CD011895-bbs2-0083){ref-type="ref-list"}).

Jacobson Vann and colleagues searched four databases to January 2017 for trials, controlled before‐after studies, and interrupted time series evaluating vaccination‐focused recipient reminders in children, adolescents, and adults in any setting. Based on 10 studies, the authors reported high‐certainty evidence that reminders improved adolescent vaccination coverage ([Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"}). There was no overlap between our review and the [Jacobson Vann 2018](#CD011895-bbs2-0092){ref-type="ref-list"} review since we excluded reminders of this kind.

Overall, our systematic review complements earlier relevant reviews, and is the most comprehensive systematic review to date on the effects of interventions for improving uptake of vaccines among adolescent boys and girls.

Authors\' conclusions {#CD011895-sec-0138}
=====================

Implications for practiceWe found that educating adolescents and their parents about the importance of vaccinations; passing laws requiring adolescents to be vaccinated as a condition for school enrolment; using a multi‐faceted package of interventions for providers of vaccination services, including education, repeated contacts, individualised feedback, and incentives; or using a class‐based approach for delivering vaccines probably increase the uptake of vaccines among adolescent girls and boys. The certainty of the evidence for these interventions was moderate, implying that monitoring and evaluation of the impact is likely to be needed.In addition, we found low‐certainty evidence that adolescent vaccination coverage may be improved through providing adolescents and their parents with financial incentives; and giving education and feedback to providers of vaccination services. The low certainty of the evidence for these interventions implies that an impact evaluation is warranted if any of these interventions is implemented to improve adolescent vaccination coverage.However, these are complex interventions which may be implemented in many different ways. For example, mandatory vaccination is context‐specific and can be operationalised through (but not limited to) schools, childcare, social welfare, and criminal justice ([Attwell 2019](#CD011895-bbs2-0070){ref-type="ref-list"}; [Omer 2019](#CD011895-bbs2-0106){ref-type="ref-list"}). The study that assessed mandatory vaccination in this review reported two key implementation challenges ([Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}). Firstly, it was complicated to track the three dose series of hepatitis B vaccinations throughout the year; especially when students moved from one school to another. Secondly, school funding was tied to school attendance, a situation which may have deterred school personnel from enforcing mandatory vaccination through exclusion of unvaccinated students.It is critical to understand the factors that influence hesitancy, acceptance, and demand for adolescent vaccination in different settings. An ongoing Cochrane qualitative evidence synthesis of factors that influence acceptance of adolescent HPV vaccination ([Cooper 2019](#CD011895-bbs2-0079){ref-type="ref-list"}) may help to explain why and how some of the interventions in the current review were more effective than others in improving uptake of HPV vaccines.

Implications for researchMost of the currently available evidence on interventions for improving adolescent vaccination coverage are from high‐income countries. In order to understand the effects of these interventions across a range of settings, there is a need for rigorous evaluations of adolescent vaccination interventions in low‐ and middle‐income countries. Given that there is little or no evidence from existing studies on cost and (gender, socioeconomic, and geographical) equity ([Table 12](#CD011895-tbl-0012){ref-type="table"}), the challenge for the future is to design rigorous evaluations and report results in ways that can assess costs and equity impacts clearly, in addition to vaccination knowledge, intentions, and coverage.In addition, there is a need for appropriately designed, implemented, and reported evaluations of interventions for which this review found low‐certainty evidence of benefits (e.g. recipient incentives, provider education and performance feedback, optimal combination of effective interventions, etc.), moderate‐certainty evidence of little or no benefits (provider prompts), and interventions for which we found no eligible studies (e.g. expansion of access to adolescent vaccination services, integration of adolescent vaccination with other services).
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**PDQ Evidence**

Title/Abstract: (\"vaccination uptake\" OR \"vaccination up take\" OR \"vaccination coverage\" OR \"vaccine uptake\" OR \"vaccine up take\" OR \"vaccine coverage\")

**CDSR, the Cochrane Library**

IDSearchHits\#1(vaccin\* and (uptake or coverage)):ti,ab507\#2(vaccin\* next uptake or vaccin\* next coverage):ti,ab265\#3\#1 or \#2507\#4MeSH descriptor: \[Immunization\] this term only661\#5MeSH descriptor: \[Immunization Schedule\] this term only984\#6MeSH descriptor: \[Immunization, Secondary\] this term only794\#7MeSH descriptor: \[Immunization Programs\] this term only391\#8MeSH descriptor: \[Immunotherapy, Active\] this term only111\#9MeSH descriptor: \[Vaccination\] this term only2456\#10MeSH descriptor: \[Mass Vaccination\] this term only78\#11\#4 or \#5 or \#6 or \#7 or \#8 or \#9 or \#104580\#12MeSH descriptor: \[Diphtheria\] this term only90\#13MeSH descriptor: \[Tetanus\] this term only166\#14MeSH descriptor: \[Bordetella Infections\] this term only5\#15MeSH descriptor: \[Bordetella pertussis\] this term only118\#16MeSH descriptor: \[Whooping Cough\] this term only228\#17MeSH descriptor: \[Measles\] this term only219\#18MeSH descriptor: \[Mumps\] this term only68\#19MeSH descriptor: \[Rubella\] this term only107\#20MeSH descriptor: \[Poliomyelitis\] this term only120\#21MeSH descriptor: \[Poliomyelitis, Bulbar\] this term only0\#22MeSH descriptor: \[Tuberculosis\] this term only743\#23MeSH descriptor: \[Tuberculosis, Pulmonary\] this term only937\#24MeSH descriptor: \[Mycobacterium tuberculosis\] this term only375\#25MeSH descriptor: \[Hepatitis A\] this term only238\#26MeSH descriptor: \[Hepatitis A virus\] this term only9\#27MeSH descriptor: \[Hepatitis A Virus, Human\] this term only32\#28MeSH descriptor: \[Hepatitis B\] this term only1238\#29MeSH descriptor: \[Hepatitis B, Chronic\] this term only933\#30MeSH descriptor: \[Hepatitis B virus\] this term only764\#31MeSH descriptor: \[Chickenpox\] this term only141\#32MeSH descriptor: \[Papillomavirus Infections\] this term only724\#33MeSH descriptor: \[Herpesviridae Infections\] this term only62\#34MeSH descriptor: \[Herpes Simplex\] this term only230\#35MeSH descriptor: \[Herpes Genitalis\] this term only366\#36MeSH descriptor: \[Herpes Labialis\] this term only134\#37MeSH descriptor: \[Herpes Zoster\] this term only361\#38MeSH descriptor: \[Meningococcal Infections\] this term only156\#39MeSH descriptor: \[Meningitis, Meningococcal\] this term only127\#40MeSH descriptor: \[Neisseria meningitidis\] this term only166\#41MeSH descriptor: \[HIV Infections\] explode all trees9351\#42MeSH descriptor: \[HIV\] this term only402\#43MeSH descriptor: \[HIV‐1\] this term only2542\#44MeSH descriptor: \[HIV‐2\] this term only25\#45MeSH descriptor: \[Neoplasms\] this term only5682\#46\#12 or \#13 or \#14 or \#15 or \#16 or \#17 or \#18 or \#19 or \#20 or \#21 or \#22 or \#23 or \#24 or \#25 or \#26 or \#27 or \#28 or \#29 or \#30 or \#31 or \#32 or \#33 or \#34 or \#35 or \#36 or \#37 or \#38 or \#39 or \#40 or \#41 or \#42 or \#43 or \#44 or \#4521,667\#47\#11 and \#461462\#48MeSH descriptor: \[Diphtheria‐Tetanus‐acellular Pertussis Vaccines\] this term only182\#49MeSH descriptor: \[Diphtheria‐Tetanus‐Pertussis Vaccine\] this term only486\#50MeSH descriptor: \[Diphtheria‐Tetanus Vaccine\] this term only63\#51MeSH descriptor: \[Pertussis Vaccine\] this term only196\#52MeSH descriptor: \[Vaccines, Combined\] this term only427\#53MeSH descriptor: \[Diphtheria Toxoid\] this term only177\#54MeSH descriptor: \[Tetanus Toxoid\] this term only385\#55MeSH descriptor: \[Measles‐Mumps‐Rubella Vaccine\] this term only152\#56MeSH descriptor: \[Measles Vaccine\] this term only231\#57MeSH descriptor: \[Mumps Vaccine\] this term only59\#58MeSH descriptor: \[Rubella Vaccine\] this term only114\#59MeSH descriptor: \[Poliovirus Vaccines\] this term only32\#60MeSH descriptor: \[Poliovirus Vaccine, Oral\] this term only149\#61MeSH descriptor: \[Poliovirus Vaccine, Inactivated\] this term only258\#62MeSH descriptor: \[Tuberculosis Vaccines\] this term only48\#63MeSH descriptor: \[BCG Vaccine\] this term only745\#64MeSH descriptor: \[Viral Hepatitis Vaccines\] this term only275\#65MeSH descriptor: \[Hepatitis A Vaccines\] this term only263\#66MeSH descriptor: \[Hepatitis B Vaccines\] this term only883\#67MeSH descriptor: \[Chickenpox Vaccine\] this term only139\#68MeSH descriptor: \[Papillomavirus Vaccines\] this term only384\#69MeSH descriptor: \[Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\] this term only55\#70MeSH descriptor: \[Meningococcal Vaccines\] this term only331\#71MeSH descriptor: \[AIDS Vaccines\] this term only391\#72\#48 or \#49 or \#50 or \#51 or \#52 or \#53 or \#54 or \#55 or \#56 or \#57 or \#58 or \#59 or \#60 or \#61 or \#62 or \#63 or \#64 or \#65 or \#66 or \#67 or \#68 or \#69 or \#70 or \#714335\#73((diphtheria\* or tetanus or bordetella or pertussis or \"whooping cough\" or measles or mumps or rubella\* or rubeola or mmr or polio\* or \"infantile paralysis\" or tuberculosis or tuberculoses or bcg or calmette\* or hepatitis or chickenpox or varicella or papilloma\* or hpv or herpes or meningococcal or meningitidis or meningitis or \"acquired immunodeficiency syndrome\" or aids or \"human immunodeficiency virus\" or hiv or cancer\* or neoplasm\*) near/3 (vaccin\* or revaccinat\* or immunization or immunisation or immunotherapy)):ti,ab6557\#74((tripe or combin\*) next vaccin\*):ti,ab339\#75\#73 or \#746622\#76\#3 or \#47 or \#72 or \#757842\#77MeSH descriptor: \[Adolescent\] this term only89,560\#78MeSH descriptor: \[Adolescent Health Services\] this term only177\#79(adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles):ti,ab20,966\#80\#77 or \#78 or \#79101,978\#81\#76 and \#80 in Cochrane Reviews (Reviews and Protocols)7

**CENTRAL, DARE and HTA, Cochrane Library**

IDSearchHits\#1vaccin\* and (uptake or coverage)942\#2(vaccin\* next uptake or vaccin\* next coverage)459\#3\#1 or \#2942\#4MeSH descriptor: \[Immunization\] this term only659\#5MeSH descriptor: \[Immunization Schedule\] this term only981\#6MeSH descriptor: \[Immunization, Secondary\] this term only792\#7MeSH descriptor: \[Immunization Programs\] this term only390\#8MeSH descriptor: \[Immunotherapy, Active\] this term only111\#9MeSH descriptor: \[Vaccination\] this term only2450\#10MeSH descriptor: \[Mass Vaccination\] this term only78\#11\#4 or \#5 or \#6 or \#7 or \#8 or \#9 or \#104569\#12MeSH descriptor: \[Diphtheria\] this term only90\#13MeSH descriptor: \[Tetanus\] this term only166\#14MeSH descriptor: \[Bordetella Infections\] this term only5\#15MeSH descriptor: \[Bordetella pertussis\] this term only118\#16MeSH descriptor: \[Whooping Cough\] this term only227\#17MeSH descriptor: \[Measles\] this term only219\#18MeSH descriptor: \[Mumps\] this term only68\#19MeSH descriptor: \[Rubella\] this term only107\#20MeSH descriptor: \[Poliomyelitis\] this term only120\#21MeSH descriptor: \[Poliomyelitis, Bulbar\] this term only0\#22MeSH descriptor: \[Tuberculosis\] this term only740\#23MeSH descriptor: \[Tuberculosis, Pulmonary\] this term only937\#24MeSH descriptor: \[Mycobacterium tuberculosis\] this term only375\#25MeSH descriptor: \[Hepatitis A\] this term only237\#26MeSH descriptor: \[Hepatitis A virus\] this term only8\#27MeSH descriptor: \[Hepatitis A Virus, Human\] this term only32\#28MeSH descriptor: \[Hepatitis B\] this term only1237\#29MeSH descriptor: \[Hepatitis B, Chronic\] this term only931\#30MeSH descriptor: \[Hepatitis B virus\] this term only760\#31MeSH descriptor: \[Chickenpox\] this term only141\#32MeSH descriptor: \[Papillomavirus Infections\] this term only722\#33MeSH descriptor: \[Herpesviridae Infections\] this term only62\#34MeSH descriptor: \[Herpes Simplex\] this term only230\#35MeSH descriptor: \[Herpes Genitalis\] this term only365\#36MeSH descriptor: \[Herpes Labialis\] this term only134\#37MeSH descriptor: \[Herpes Zoster\] this term only361\#38MeSH descriptor: \[Meningococcal Infections\] this term only156\#39MeSH descriptor: \[Meningitis, Meningococcal\] this term only127\#40MeSH descriptor: \[Neisseria meningitidis\] this term only166\#41MeSH descriptor: \[HIV Infections\] explode all trees9328\#42MeSH descriptor: \[HIV\] this term only402\#43MeSH descriptor: \[HIV‐1\] this term only2535\#44MeSH descriptor: \[HIV‐2\] this term only25\#45MeSH descriptor: \[Neoplasms\] this term only5662\#46\#12 or \#13 or \#14 or \#15 or \#16 or \#17 or \#18 or \#19 or \#20 or \#21 or \#22 or \#23 or \#24 or \#25 or \#26 or \#27 or \#28 or \#29 or \#30 or \#31 or \#32 or \#33 or \#34 or \#35 or \#36 or \#37 or \#38 or \#39 or \#40 or \#41 or \#42 or \#43 or \#44 or \#4521,613\#47\#11 and \#461459\#48MeSH descriptor: \[Diphtheria‐Tetanus‐acellular Pertussis Vaccines\] this term only182\#49MeSH descriptor: \[Diphtheria‐Tetanus‐Pertussis Vaccine\] this term only486\#50MeSH descriptor: \[Diphtheria‐Tetanus Vaccine\] this term only63\#51MeSH descriptor: \[Pertussis Vaccine\] this term only196\#52MeSH descriptor: \[Vaccines, Combined\] this term only427\#53MeSH descriptor: \[Diphtheria Toxoid\] this term only177\#54MeSH descriptor: \[Tetanus Toxoid\] this term only385\#55MeSH descriptor: \[Measles‐Mumps‐Rubella Vaccine\] this term only152\#56MeSH descriptor: \[Measles Vaccine\] this term only231\#57MeSH descriptor: \[Mumps Vaccine\] this term only59\#58MeSH descriptor: \[Rubella Vaccine\] this term only114\#59MeSH descriptor: \[Poliovirus Vaccines\] this term only32\#60MeSH descriptor: \[Poliovirus Vaccine, Oral\] this term only149\#61MeSH descriptor: \[Poliovirus Vaccine, Inactivated\] this term only258\#62MeSH descriptor: \[Tuberculosis Vaccines\] this term only48\#63MeSH descriptor: \[BCG Vaccine\] this term only743\#64MeSH descriptor: \[Viral Hepatitis Vaccines\] this term only275\#65MeSH descriptor: \[Hepatitis A Vaccines\] this term only262\#66MeSH descriptor: \[Hepatitis B Vaccines\] this term only883\#67MeSH descriptor: \[Chickenpox Vaccine\] this term only139\#68MeSH descriptor: \[Papillomavirus Vaccines\] this term only381\#69MeSH descriptor: \[Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\] this term only55\#70MeSH descriptor: \[Meningococcal Vaccines\] this term only331\#71MeSH descriptor: \[AIDS Vaccines\] this term only391\#72\#48 or \#49 or \#50 or \#51 or \#52 or \#53 or \#54 or \#55 or \#56 or \#57 or \#58 or \#59 or \#60 or \#61 or \#62 or \#63 or \#64 or \#65 or \#66 or \#67 or \#68 or \#69 or \#70 or \#714329\#73(diphtheria\* or tetanus or bordetella or pertussis or \"whooping cough\" or measles or mumps or rubella\* or rubeola or mmr or polio\* or \"infantile paralysis\" or tuberculosis or tuberculoses or bcg or calmette\* or hepatitis or chickenpox or varicella or papilloma\* or hpv or herpes or meningococcal or meningitidis or meningitis or \"acquired immunodeficiency syndrome\" or aids or \"human immunodeficiency virus\" or hiv or cancer\* or neoplasm\*) near/3 (vaccin\* or revaccinat\* or immunization or immunisation or immunotherapy)8741\#74(tripe or combin\*) next vaccin\*362\#75\#73 or \#748791\#76\#3 or \#47 or \#72 or \#759346\#77MeSH descriptor: \[Adolescent\] this term only89,013\#78MeSH descriptor: \[Adolescent Health Services\] this term only177\#79(adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles)141,801\#80\#77 or \#78 or \#79141,801\#81\#76 and \#80 in Technology Assessments4\#82\#76 and \#80 in Other Reviews33\#83\#76 and \#80 in Trials1807

**MEDLINE, Ovid**

**\#SearchesResults**1(vaccin\* and (uptake or coverage)).ti.24902(vaccin\* adj (uptake or coverage)).ab.67673or/1‐277804Immunization/47,4105Immunization Schedule/95596Immunization, Secondary/75287Immunization Programs/87368Immunotherapy, Active/24159Vaccination/70,95710Mass Vaccination/262211or/4‐10133,94912Diphtheria/648013Tetanus/922714Bordetella Infections/92415Bordetella Pertussis/488016Whooping Cough/768417Measles/12,54618Mumps/423719Rubella/749720Poliomyelitis/18,66021Poliomyelitis, Bulbar/90822Tuberculosis/98,03823Tuberculosis, Pulmonary/71,50124Mycobacterium Tuberculosis/43,34225Hepatitis A/20,03426Hepatitis A virus/100027Hepatitis A Virus, Human/51928Hepatitis B/39,63929Hepatitis B, Chronic/12,44830Hepatitis B virus/22,92131Chickenpox/699532Papillomavirus Infections/20,04533Herpesviridae Infections/13,58034Herpes Simplex/13,42135Herpes Genitalis/442636Herpes Labialis/113937Herpes Zoster/934538Meningococcal Infections/565539Meningitis, Meningococcal/487540Neisseria meningitidis/757541exp HIV Infections/253,90742HIV/17,42343HIV‐1/71,57944HIV‐2/396345Neoplasms/370,68246or/12‐451,012,9454711 and 4633,25148Diphtheria‐Tetanus‐Acellular Pertussis Vaccines/97949Diphtheria‐Tetanus‐Pertussis Vaccine/263350Diphtheria‐Tetanus Vaccine/37651Pertussis Vaccine/484252Vaccines, Combined/215553Diphtheria Toxoid/298554Tetanus Toxoid/906355Measles‐Mumps‐Rubella Vaccine/238256Measles Vaccine/625257Mumps Vaccine/160458Rubella Vaccine/289559Poliovirus Vaccines/147160Poliovirus Vaccine, Oral/374361Poliovirus Vaccine, Inactivated/269662Tuberculosis Vaccines/150963BCG Vaccine/18,20964Viral Hepatitis Vaccines/336665Hepatitis A Vaccines/155366Hepatitis B Vaccines/840167Chickenpox Vaccine/179168Papillomavirus Vaccines/570569Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/63070Meningococcal Vaccines/290071AIDS Vaccines/732672or/48‐7178,77073((diphtheria? or tetanus or bordetella or pertussis or whooping cough or measles or mumps or rubella? or rubeola or mmr or polio\* or infantile paralysis or tuberculosis or tuberculoses or bcg or calmette\* or hepatitis or chickenpox or varicella or papilloma\* or hpv or herpes or meningococcal or meningitidis or meningitis or acquired immunodeficiency syndrome or aids or human immunodeficiency virus or hiv? or cancer? or neoplasm?) adj3 (vaccin\* or revaccinat\* or immunization or immunisation or immunotherapy)).ti,ab,kf.83,99074((tripe or combin\*) adj vaccin\*).ti,ab,kf.186575or/73‐7484,971763 or 47 or 72 or 75129,19577Adolescent/1,791,25678Adolescent Health Services/497079(adolescent? or youth? or young adult? or teenager? or teen? or juvenile?).ti,ab,kf.370,76580or/77‐791,944,2368176 and 8021,37782randomized controlled trial.pt.450,37183controlled clinical trial.pt.92,10884multicenter study.pt.220,18885pragmatic clinical trial.pt.52786non‐randomized controlled trials as topic/12487interrupted time series analysis/24188controlled before‐after studies/21689(randomis\* or randomiz\* or randomly).ti,ab.727,55290groups.ab.1,678,66691(trial or intervention? or effect? or impact? or multicenter or multi center or multicentre or multi centre).ti.1,999,73792(controlled or control group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) and (posttest or post test)) or quasiexperiment\* or quasi experiment\* or evaluat\* or time series or time point? or repeated measur\*).ti,ab.3,813,64093or/82‐926,451,39994exp Animals/20,778,90995Humans/16,453,1689694 not (94 and 95)4,325,74197review.pt.2,231,73898meta analysis.pt.74,57199news.pt.180,934100comment.pt.680,643101editorial.pt.426,869102cochrane database of systematic reviews.jn.12,989103comment on.cm.680,642104(systematic review or literature review).ti.90,912105or/96‐1047,545,35910693 not 1054,704,29210781 and 1067694

**Embase, Ovid**

**\#SearchesResults**1(vaccin\* and (uptake or coverage)).ti.28742(vaccin\* adj (uptake or coverage)).ab.77783or/1‐289954vaccination/141,2855immunization/101,6646mass immunization/34427or/4‐6222,28183 or 7224,1789adolescent/1,421,54110juvenile/62,74611(adolescent? or youth? or young adult? or teenager? or teen? or juvenile?).ti,ab.450,61712or/9‐111,599,735138 and 1219,04114Randomized Controlled Trial/479,70515Controlled Clinical Trial/475,29416Quasi Experimental Study/442217Pretest Posttest Control Group Design/35318Time Series Analysis/24,35419Experimental Design/25,55520Multicenter Study/164,86221(randomis\* or randomiz\* or randomly).ti,ab.964,28322groups.ab.2,227,94623(trial or intervention? or effect? or impact? or multicenter or multi center or multicentre or multi centre).ti.2,390,55324(controlled or control group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) and (posttest or post test)) or quasiexperiment\* or quasi experiment\* or evaluat\* or time series or time point? or repeated measur\*).ti,ab.5,069,45225or/14‐248,222,05726exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/24,477,25627human/ or normal human/ or human cell/18,584,4672826 and 2718,537,6292926 not 285,939,62730(systematic review or literature review).ti.108,09331\"cochrane database of systematic reviews\".jn.563432or/29‐316,052,5693325 not 326,461,1203413 and 33734035limit 34 to embase196136limit 34 to embase status6513735 or 362134

**CINAHL, EBSCOhost**

**\#QueryResults**S31S29 AND S3017S30EM 201510‐173,379S29S11 AND S27 \[Limiters: Exclude MEDLINE records\]194S28S11 AND S271430S27S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S261,355,101S26TI ( controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\* ) OR AB ( controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\* )378,261S25TI ( trial or intervention\* or effect\* or impact\* or multicenter or \"multi center\" or multicentre or \"multi centre\" ) OR AB ( trial or intervention\* or effect\* or impact\* or multicenter or \"multi center\" or multicentre or \"multi centre\" )668,977S24TI ( randomis\* or randomiz\* or randomly) OR AB ( randomis\* or randomiz\* or randomly)120,324S23(MH \"Health Services Research\")7568S22(MH \"Multicenter Studies\")21,717S21(MH \"Quasi‐Experimental Studies+\")8885S20(MH \"Pretest‐Posttest Design+\")28,056S19(MH \"Experimental Studies\")15,256S18(MH \"Nonrandomized Trials\")183S17(MH \"Intervention Trials\")6179S16(MH \"Clinical Trials\")87,623S15(MH \"Randomized Controlled Trials\")30,257S14PT research995,947S13PT clinical trial52,904S12PT randomized controlled trial30,868S11S6 AND S102949S10S7 OR S8 OR S9257,799S9TI ( adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles ) OR AB ( adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles )80,203S8(MH \"Adolescent Health Services\")1661S7(MH \"Adolescence\")236,921S6S1 OR S2 OR S3 OR S416,710S5TI ( vaccin\* and (uptake or coverage) ) OR AB ( vaccin\* and (uptake or coverage) )2167S4(MH \"Immunization Programs\")3166S3(MH \"Immunization, Secondary\")93S2(MH \"Immunization Schedule\")2003S1(MH \"Immunization\")13,171

**Global Health, Ovid**

**\#SearchesResults**1(vaccin\* and (uptake or coverage)).ti.17052(vaccin\* adj (uptake or coverage)).ab.51223or/1‐256044vaccination.cw,hw,id.53,6955(immunisation or immunization).cw,hw,id.59,2346or/4‐568,00473 or 668,5338adolescents/45,3039young adults/936310youth/991011(adolescent? or youth? or young adult? or teenager? or teen? or juvenile?).ti,ab,cw,hw,id.81,37612or/8‐1181,376137 and 12356314(trial or intervention? or effect? or impact? or multicenter or multi center or multicentre or multi centre).ti.307,55015(randomiz\* or randomis\* or controlled or control group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) and (posttest or post test)) or quasiexperiment\* or quasi experiment\* or evaluat\* or time series or time point? or repeated measur\*).ti,ab,cw,hw,id.637,04916or/14‐15819,6141713 and 161294

**Africa‐Wide Information, EBSCOhost**

**\#QueryResults**S20S8 AND S13 AND S1972S19S14 OR S15 OR S16 OR S17 OR S18599,804S18TI ( (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*) ) OR AB ( (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*) )557,235S17TP (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*)948S16SU (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*)73,881S15SM (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*)9392S14KW (randomis\* or randomiz\* or randomly or trial or effect\* or impact\* or intervention\* or controlled or control W0 group\* or before N5 after or pre N5 post or ((pretest or \"pre test\") and (posttest or \"post test\")) or quasiexperiment\* or quasi W0 experiment\* or evaluat\* or \"time series\" or time W0 point\* or repeated W0 measur\*)74,045S13S9 OR S10 OR S11 OR S1276,308S12TI ( (adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles) ) OR AB ( (adolescent\* or youth\* or young adult\* or teenager\* or teen or teens or juvenile or juveniles) ) OR AB ( (adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles) ) OR AB ( (adolescent\* or youth\* or young adult\* or teenager\* or teen or teens or juvenile or juveniles) )43,801S11SU adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles64,994S10SM adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles62,957S9KW adolescent\* or youth\* or \"young adult\" or \"young adults\" or teenager\* or teen or teens or juvenile or juveniles64,992S8S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S76952S7TI ( vaccin\* and (uptake or coverage) ) OR AB ( vaccin\* and (uptake or coverage) )2129S6SU immunization994S5SM immunization0S4KW immunization2012S3SU vaccination3036S2SM vaccination0S1KW vaccination3365

**Scopus, Elsevier**

( TITLE‐ABS‐KEY ( ( vaccination W/3 adolescent\* ) OR ( vaccination W/3 youth\* ) OR ( vaccination W/3 {young adult} ) OR ( vaccination W/3 {young adults} ) OR ( vaccination W/3 teenager\* ) OR ( immunization W/3 adolescent\* ) OR ( immunization W/3 youth\* ) OR ( immunization W/3 {young adult} ) OR ( immunization W/3 {young adults} ) OR ( immunization W/3 teenager\* ) OR ( immunisation W/3 adolescent\* ) OR ( immunisation W/3 youth\* ) OR ( immunisation W/3 {young adult} ) OR ( immunisation W/3 {young adults} ) OR ( immunisation W/3 teenager\* ) ) ) AND ( ( TITLE‐ABS‐KEY ( randomis\* OR randomiz\* OR randomly OR intervention\* OR control\* OR evaluat\* OR {before and after} OR ( ( {pre test} OR {pretest} ) AND ( {post test} OR posttest ) ) OR quasiexperiment\* OR ( quasi W/0 experiment\* ) OR {time series} OR ( time W/0 point\* ) OR ( repeated W/0 measur\* ) ) ) OR ( TITLE ( trial OR effect\* OR impact\* ) ) )

**Grey literature**

(Interventions) AND (adolescent) AND (immunisation)

**Trial registries:**

(With all the words (( interventions AND adolescent AND immunisation)))

**MethodApproachMeasures of treatment effects**We will express the result of each study as a mean difference with its 95% confidence intervals for continuous data. We will analyse interrupted time series (ITS) studies using a regression analysis with time trends before and after the interventions. We will present the results for the outcomes as change in level and slope ([Ramsay 2003](#CD011895-bbs2-0111){ref-type="ref-list"}).**Unit of analysis issues**If investigators report cluster‐randomised trial data as if the randomisation was performed on the individuals rather than the clusters, we will request the intracluster correlation coefficient (ICC) from the study authors; failing this, we will obtain external estimates of the ICC from similar studies or available resources ([Campbell 2000](#CD011895-bbs2-0076){ref-type="ref-list"}).\
Once established, we will use the ICC to reanalyse the trial data to obtain approximate correct analyses. We will adjust the data by inflating the standard errors, i.e. multiplying them by the square root of the design effect ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}). We plan to report the effect estimates and the corrected standard errors from cluster‐randomised trials with those from parallel‐group design trials, noting that the analysis of data from that specific study had a unit of analysis error ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}). If insufficient information is available to control for clustering in this way, we will enter data into Review Manager 5 using individuals as the unit of analysis ([Review Manager 2014](#CD011895-bbs2-0112){ref-type="ref-list"}). We will then perform sensitivity analyses to assess the potential bias that may have occurred as a result of the inadequately controlled clustered trials. We will also perform sensitivity analyses if we obtained the ICCs from external sources, to assess the potential biasing effects of inadequately controlled cluster‐randomised  trials ([Donner 2001](#CD011895-bbs2-0081){ref-type="ref-list"}).**Dealing with missing data**Where necessary, we will contact the corresponding authors of included studies to supply any unreported data. We will describe missing data and dropouts for each included study in a \'Risk of bias\' table, and discuss the extent to which the missing data could alter our results. For controlled before‐after studies where relative measures are not available, we will estimate the difference between outcome measures at 2 time points for both baseline and after the intervention and then compare the difference between the groups. In contrast, if interrupted ITS are incorrectly analysed by the authors and provide the data points, we will reanalyse them using a regression analysis with time trends before and after the intervention, which adjust for autocorrelation and any periodic change ([Ramsay 2003](#CD011895-bbs2-0111){ref-type="ref-list"}).**Assessment of reporting bias**We will use a funnel plot to investigate the risk of publication bias by intervention type, provided ≥ 10 studies are included in the analysis for each intervention type. We will critically examine the funnel plot for asymmetry both visually and with the use of formal tests. For continuous outcomes, we will use the test proposed by Egger ([Egger 1997](#CD011895-bbs2-0082){ref-type="ref-list"}), and for dichotomous outcomes, we will use the test proposed by Harbord ([Higgins 2019](#CD011895-bbs2-0091){ref-type="ref-list"}). In situations where asymmetry is detected by either test or by visual assessment, we will perform further exploratory analyses to investigate it. This will include reviewing the included studies for small sample size studies and their intervention effect.**Data synthesis**We will report unit of analysis error studies as changes in level and slope. If ITS studies are incorrectly analysed by the authors and provide the data points, we will reanalyse them using a regression analysis with time trends before and after the intervention, which adjust for autocorrelation and any periodic change.**Subgroup analysis and investigation of heterogeneity**Where sufficient data are available, we will conduct subgroup analyses, which will explore the effects of: vaccine given including frequency of the vaccine; availability of a policy on adolescent vaccination including vaccination schedule; equity (school‐based interventions or mass campaign programmes); and country income status (World Bank classification as either high‐income countries or low‐ to middle‐income countries).**Sensitivity analysis**Where sufficient data are available, we will conduct, if applicable, a sensitivity analysis to establish whether the meta‐analysis results for the treatment effect are influenced by study designs and overall risk of bias. We will perform sensitivity analyses by excluding studies with a particular study design and studies with high risk of bias.

###### Comparison 1: health education compared to usual practice

  Outcome or subgroup title                                                     No. of studies   No. of participants   Statistical method                 Effect size
  ----------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Human papillomavirus vaccine uptake](#CD011895-fig-0005){ref-type="fig"}   4                                      Risk Ratio (M‐H, Random, 95% CI)   Subtotals only
  1.1 Non‐randomised                                                            1                2822                  Risk Ratio (M‐H, Random, 95% CI)   1.84 \[1.34, 2.54\]
  1.2 Randomised                                                                3                1054                  Risk Ratio (M‐H, Random, 95% CI)   1.43 \[1.16, 1.76\]

![Analysis\
Comparison 1 Comparison 1: health education compared to usual practice, Outcome 1 Human papillomavirus vaccine uptake.](nCD011895-CMP-001-01){#CD011895-fig-0005}

###### Comparison 2: complex compared to simplified health education

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                 Effect size
  -------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Hepatitis B vaccine uptake](#CD011895-fig-0006){ref-type="fig"}   1                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected

![Analysis\
Comparison 2 Comparison 2: complex compared to simplified health education, Outcome 1 Hepatitis B vaccine uptake.](nCD011895-CMP-002-01){#CD011895-fig-0006}

###### Comparison 3: financial incentives compared to usual practice

  Outcome or subgroup title                                                     No. of studies   No. of participants   Statistical method                 Effect size
  ----------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Human papillomavirus vaccine uptake](#CD011895-fig-0007){ref-type="fig"}   1                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected

![Analysis\
Comparison 3 Comparison 3: financial incentives compared to usual practice, Outcome 1 Human papillomavirus vaccine uptake.](nCD011895-CMP-003-01){#CD011895-fig-0007}

###### Comparison 4: health education plus financial incentives compared to usual practice

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                 Effect size
  -------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Hepatitis B vaccine uptake](#CD011895-fig-0008){ref-type="fig"}   1                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected

![Analysis\
Comparison 4 Comparison 4: health education plus financial incentives compared to usual practice, Outcome 1 Hepatitis B vaccine uptake.](nCD011895-CMP-004-01){#CD011895-fig-0008}

###### Comparison 5: mandatory vaccination compared to usual practice

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                 Effect size
  -------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Hepatitis B vaccine uptake](#CD011895-fig-0009){ref-type="fig"}   1                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected
  1.1 9th graders in Missouri vs Kansas                                1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]
  1.2 9th graders in Missouri vs 12th graders in Missouri              1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 5 Comparison 5: mandatory vaccination compared to usual practice, Outcome 1 Hepatitis B vaccine uptake.](nCD011895-CMP-005-01){#CD011895-fig-0009}

###### Comparison 6: provider prompts compared to usual practice

  Outcome or subgroup title                                                                              No. of studies   No. of participants   Statistical method           Effect size
  ------------------------------------------------------------------------------------------------------ ---------------- --------------------- ---------------------------- ---------------------
  [1 Human papillomavirus vaccine uptake](#CD011895-fig-0010){ref-type="fig"}                            1                                      Odds Ratio (Fixed, 95% CI)   0.99 \[0.55, 1.81\]
  [2 Tetanus--diphtheria--acellular--pertussis vaccination uptake](#CD011895-fig-0011){ref-type="fig"}   1                                      Odds Ratio (Fixed, 95% CI)   1.28 \[0.59, 2.80\]
  [3 Meningococcal conjugate vaccination uptake](#CD011895-fig-0012){ref-type="fig"}                     1                                      Odds Ratio (Fixed, 95% CI)   1.09 \[0.67, 1.79\]
  [4 Seasonal influenza vaccination uptake](#CD011895-fig-0013){ref-type="fig"}                          1                                      Odds Ratio (Fixed, 95% CI)   0.91 \[0.61, 1.34\]

![Analysis\
Comparison 6 Comparison 6: provider prompts compared to usual practice, Outcome 1 Human papillomavirus vaccine uptake.](nCD011895-CMP-006-01){#CD011895-fig-0010}

![Analysis\
Comparison 6 Comparison 6: provider prompts compared to usual practice, Outcome 2 Tetanus--diphtheria--acellular--pertussis vaccination uptake.](nCD011895-CMP-006-02){#CD011895-fig-0011}

![Analysis\
Comparison 6 Comparison 6: provider prompts compared to usual practice, Outcome 3 Meningococcal conjugate vaccination uptake.](nCD011895-CMP-006-03){#CD011895-fig-0012}

![Analysis\
Comparison 6 Comparison 6: provider prompts compared to usual practice, Outcome 4 Seasonal influenza vaccination uptake.](nCD011895-CMP-006-04){#CD011895-fig-0013}

###### Comparison 8: class‐based compared to age‐based HPV vaccination in schools

  Outcome or subgroup title                                                     No. of studies   No. of participants   Statistical method                 Effect size
  ----------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Human papillomavirus vaccine uptake](#CD011895-fig-0014){ref-type="fig"}   1                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected

![Analysis\
Comparison 7 Comparison 8: class‐based compared to age‐based HPV vaccination in schools, Outcome 1 Human papillomavirus vaccine uptake.](nCD011895-CMP-007-01){#CD011895-fig-0014}

###### Comparison 10: multi‐component provider and parent intervention compared to usual practice

  Outcome or subgroup title                                                     No. of studies   No. of participants   Statistical method                 Effect size
  ----------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Human papillomavirus vaccine uptake](#CD011895-fig-0015){ref-type="fig"}   2                                      Risk Ratio (M‐H, Random, 95% CI)   Totals not selected
  1.1 Randomised                                                                1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]
  1.2 Non‐randomised                                                            1                                      Risk Ratio (M‐H, Random, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 8 Comparison 10: multi‐component provider and parent intervention compared to usual practice, Outcome 1 Human papillomavirus vaccine uptake.](nCD011895-CMP-008-01){#CD011895-fig-0015}

Characteristics of included studies \[ordered by study ID\] {#CD011895-sec-0153}
===========================================================

[Cates 2014](#CD011895-bbs2-0001){ref-type="ref-list"}MethodsNon‐randomised trial conducted in the USAParticipants**Participants:** parents and health providers\
**Number per group:** 19,842 boys in intervention group and 6027 boys in control group\
**Total number enrolled:** 28,869\
**Study population:** healthcare providers and parents of boys aged 9--13 year in a 13‐county region in North CarolinaInterventions**Intervention:** social marketing intervention\
**Description:** intervention included: (1) distribution of HPV vaccination posters and brochures with the risk‐related message to health departments plus health providers; (2) 2 radio public service announcements in both English and Spanish designed to raise awareness about HPV vaccine for boys among parents of preteen boys; (3) an online continuing medical education training with video demonstrating communication among providers, parents, and preteen boys available to enrolled health providers; (4) 1‐page tip sheet for providers to discuss HPV vaccination with parents and boys; and (5) a website (protecthim.org) with links to credible information sources useful for both parents and providers.\
**Duration:** 3 months\
**Comparison:** usual practice\
**Description of comparison:** none\
**Vaccine target:** HPV vaccines\
**Disease targeted:** cervical cancer\
**Number of doses:** 3OutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNo randomisation.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesUnclear riskNo description.Selective reporting (reporting bias)Low riskNo selective reporting.Other biasLow riskNo evidence of other biases.[Diclemente 2015](#CD011895-bbs2-0002){ref-type="ref-list"}MethodsRandomised trial conducted in the USAParticipants**Participants:** adolescent girls\
**Number per group:** 108 in \"Girls OnGuard\" intervention group and 108 in health promotion comparison group\
**Total number enrolled:** 216 participants\
**Study population:** African American adolescent girls attending 5 health clinics in metropolitan Atlanta between 2010 and 2012.Interventions**Intervention: \"**Girls OnGuard\"\
**Description:** participants viewed a 12‐minute interactive computer‐delivered media presentation on HPV vaccination designed to enhance initial uptake and completion of the full series of 4 doses of HPV. This presentation was culture‐ and gender‐sensitive. Study procedures were initiated and completed while participants waited in the clinic waiting area to receive health services.\
**Duration:** 30 minutes\
**Comparison:** usual practice\
**Description of comparison:** participants viewed a time‐equivalent health promotion media presentation on physical activity and nutrition. The videos were designed to be gender and culturally appropriate, beneficial, and engaging.\
**Vaccine target:** HPV vaccine\
**Disease targeted:** cervical cancer\
**Number of doses:** 4 dosesOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomisation using prepackaged unmarked envelopes containing solid blue (intervention group) or purple (comparison group) slips of paper.Allocation concealment (selection bias)Low riskUnmarked envelopes with colour coding that was based on a randomisation scheme that was created by computer algorithm, designed to eliminate bias in assigning participants to study conditions.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskAll clinic providers were blind to study intervention conditions and provided standard of care counselling to all participants in accordance with clinic protocol.Incomplete outcome data (attrition bias)   All outcomesLow riskOutcome data were complete.Selective reporting (reporting bias)Low riskNo follow‐up assessments incorporated into the study procedure, as this was a purposive method to minimise reactivity and reporting bias, such as social desirability bias.Other biasLow riskNo evidence of other biases.[Fiks 2016](#CD011895-bbs2-0003){ref-type="ref-list"}MethodsControlled before‐after study conducted in the USAParticipants**Participants:** providers\
**Number per group:** 27 MOC paediatricians and 200 \"usual care\" paediatricians\
**Total number enrolled:** 227 paediatricians\
**Study population:** Children\'s Hospital of Philadelphia primary care network comprising 227 primary care clinicians practicing at 27 practices at 31 sites, caring for \> 200,000 children in Pennsylvania and New Jersey. All practices shared a common EHR (EpicCare, Verona, WI).Interventions**Intervention:** MOC programmes using education and performance feedback\
**Description:** paediatricians received education and EHR‐generated performance feedback reports with their rates of captured HPV immunisation opportunities (dose given at eligible visit). The educational component consisted of a 1‐hour webinar that described current vaccination rates in the network, data on vaccine safety and efficacy, and strategies for overcoming barriers to vaccine receipt. Providers enrolled in the MOC project received quarterly performance feedback reports, extracted from EHRs, summarising their own, their practices\', and the network\'s rates of missed HPV vaccination opportunities. Participating clinicians, drawn from practices across the network, met quarterly in a lunch‐hour teleconference to review the results of performance feedback and decide on an area of improvement for the next quarter.\
**Duration:** 1 year\
**Comparison:** usual practice\
**Description of comparison:** paediatricians did not receive the MOC programme.\
**Vaccine target:** HPV vaccine\
**Disease targeted:** cervical cancer\
**Number of doses:** 3 dosesOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNo randomisation.Allocation concealment (selection bias)High riskNo allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo attrition bias.Selective reporting (reporting bias)Low riskNo reporting bias.Other biasLow riskNo evidence of other biases.[Gargano 2015](#CD011895-bbs2-0004){ref-type="ref-list"}MethodsRandomised trial in the USA between November 2011 and July 2013Participants**Participants:** parents of middle‐ and high‐school students\
**Number enrolled:** 6 middle‐ and 5 high‐schools\
**Study population:** parents of middle‐ and high‐school students enrolled in schools that were participating in a study focused on evaluating approaches to promoting adolescent vaccination.Interventions**Intervention:** 1. parent‐only adolescent vaccination education and 2. parent and adolescent education\
**Description:** 3‐ to 5‐month health education for parents only or parents and adolescents. The intervention consisted of a brochure for parents and a 2‐ to 3‐day curriculum for adolescents. The parent education package included an invitation letter and a gift card valued at USD 20.\
**Duration:** 2 years\
**Comparison:** usual practice\
**Description of the comparison:** none.\
**Vaccine target:** Tdap, meningococcal, HPV, and influenza vaccines\
**Disease targeted:** not specified\
**Number of doses:** not statedOutcomesParent willingness to have their adolescent vaccinated in a school‐located vaccination clinic\
Attitudes and beliefs towards vaccinationNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesHigh riskLow response rate.Selective reporting (reporting bias)Unclear riskNo description.Other biasLow riskNo evidence of other biases.[Grandahl 2016](#CD011895-bbs2-0005){ref-type="ref-list"}MethodsCluster randomised trial conducted in SwedenParticipants**Participants:** 16‐year old girls and boys\
**Number per group:** 390 students from 60 classes in intervention group and 351 students from 53 classes in a control group.\
**Total number enrolled:** 741 adolescents\
**Study population:** Swedish upper secondary school adolescents aged 16--19 yearsInterventions**Intervention:** face‐to‐face health education\
**Description:** face‐to‐face structured information about HPV, including cancer risks and HPV prevention, by propagating condom use and HPV vaccination.\
**Duration:** 30 minutes\
**Comparison:** usual practice\
**Description of comparison:** general information, including sexual health\
**Vaccine target:** HPV vaccine\
**Disease targeted:** cervical cancer\
**Number of doses:** not specifiedOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomisation was performed in 2 steps. First, in order to avoid contamination, the schools were randomised into either the intervention group or the control group. Second, 113 school classes within these schools were randomly selected to be included in the study.Allocation concealment (selection bias)Low riskSchools were randomly drawn by administrative personnel not involved in the project.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskResearch assistant who recorded the data from the participants did not possess this knowledge.Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up.Selective reporting (reporting bias)Low riskDue to the self‐reported questionnaires, there was a risk of participants\' over‐reporting or under‐reporting or having recall bias; however, we consider this risk to be small in this study.Other biasLow riskNo evidence of other biases.[Mantzari 2015](#CD011895-bbs2-0006){ref-type="ref-list"}MethodsParallel‐group randomised controlled trial conducted in the UKParticipants**Participants:** girls aged 16--18 years\
**Number per group:** 500 girls had not yet received an invitation to attend the vaccination programmes (first‐time invitees), and 500 girls had previously received an invitation to get vaccinated, but had failed to attend the first vaccination appointment (previous non‐attenders).\
**Total number enrolled:** 1000 girls\
**Study population:** all girls lived in Birmingham, UK, and were registered with general practitioners; were eligible to be vaccinated; and had not been vaccinated against HPV before.Interventions**Intervention:** financial incentive with standard practice in combination with reminder text messages\
**Description:** participants received invitation letters addressed to them and inviting them to attend first HPV vaccination session. The letters included the date, time, and venue of their allocated vaccination appointment. In addition to the invitation letters, all participants were sent a standard leaflet containing information about HPV and the HPV vaccine. Participants in the intervention groups received an invitation letter with an enclosed offer of Love2Shop vouchers worth GBP 45 upon completion of 3 HPV vaccination doses.\
**Duration:** 6 months\
**Comparison:** standard practice with no incentives and no reminder system\
**Description of comparison:** letters, addressed to participants, inviting them to attend their first HPV vaccination session. In addition, the participants were sent a leaflet containing information about HPV and the HPV vaccine.\
**Vaccine target:** HPV vaccines\
**Disease targeted:** cervical cancer, genital wart\
**Number of doses:** 1‐3 dosesOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom sequence generation done using the RAND function in Excel.Allocation concealment (selection bias)Low riskParticipants allocated to the intervention and control group using the RAND function in Excel.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskVaccinations administered by nurses working with Heart of Birmingham Primary Care Trust.Incomplete outcome data (attrition bias)   All outcomesLow riskNo lost to follow‐up.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other biases.[Paskett 2016](#CD011895-bbs2-0007){ref-type="ref-list"}MethodsRandomized trial conducted in the USAParticipants**Participants:** parents and providers\
**Number per group:** of the 337 parents, 174 in intervention group and 163 in control group. Of the 119 providers, 57 in intervention group and 62 in control group\
**Total number enrolled:** 337 parents and 119 providers\
**Study population:** a group‐randomised trial among 12 counties in Appalachian Ohio were conducted. Parents who had a daughter aged 9--17 years who had not received the HPV vaccine were recruited. Providers from these 12 county clinics were also recruited.Interventions**Intervention:** educational HPV vaccine intervention\
**Description:** the intervention included:\
provider‐level intervention: the educational session for providers, facilitated by a member of the research team, included a 1‐hour PowerPoint presentation and handouts on the HPV vaccine, focusing on current evidence‐based HPV vaccine information and strategies designed to assist physicians in discussing HPV vaccination with parents;parent‐level intervention: intervention participants were mailed a packet that included an educational brochure and DVD video about HPV and HPV vaccination and a CDC HPV vaccine information statement. Health educators conducted an education session about the HPV vaccine via telephone to reinforce the message in the educational materials regarding the need for a vaccine and addressed any vaccination barriers or questions.\
**Duration:** no description\
**Comparison:** educational intervention on influenza vaccine\
**Description of comparison:**\
provider‐level control: for the comparison arm, providers were given information on the influenza and influenza vaccine;parent‐level control: the comparison group was mailed a packet that included an influenza vaccine information statement from the CDC and influenza information sheets. Health educators conducted an education session about influenza vaccine via telephone to reinforce the message in the educational materials regarding the need for a vaccine and addressed any vaccination barriers or questions.\
**Vaccine target:** cervical cancer\
**Disease targeted:** HPV vaccine\
**Number of doses:** 3 dosesOutcomesHPV vaccine uptake\
Knowledge on HPV vaccinationNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCounties were pair‐matched based on cervical cancer incidence rates and location. 1 county from each pair was randomly assigned to receive the intervention whereas the other county was assigned to the comparison condition.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo attrition bias.Selective reporting (reporting bias)Low riskNo selective reporting bias.Other biasLow riskNo evidence of other biases.[Perkins 2015](#CD011895-bbs2-0008){ref-type="ref-list"}MethodsCluster randomised trial in the USAParticipants**Participants:** healthcare providers and their patients including boys and girls aged 11--21 years\
**Number per group:** 2 intervention health centres (4093 participants) and 6 control health centres (9025 participants)\
**Total number enrolled:** 13,118 participants\
**Study population:** healthcare workers (physicians, nurse practitioners, nurses, physician assistants, and medical assistants). Only physicians, nurse practitioners, and physician assistants with their own patient panels were eligible to receive personalised feedback on vaccination rates. As an incentive, physicians were eligible to receive maintenance of certification (MOC) Part IV credits, which fulfilled the requirements for maintaining board certification. Boys and girls aged 11--21 years from low‐income populations who received primary care in the Pediatric/Adolescent Departments at an intervention or control practice.Interventions**Intervention:** multi‐component performance improvement continuing medical education intervention\
**Description:** intervention included:\
6--8 education visits over 12 months by an HPV physician‐educator;focused education sessions on HPV‐related topics designed to change the way providers viewed the importance of HPV vaccination and responded to parents\' hesitation toward HPV vaccines;individualised feedback where providers and practices received individual reports that showed their performance compared to other providers in their practice on HPV vaccination coverage. Those practices that showed initiatives to improve systems for HPV series completion were given support;quality improvement incentives where physicians were eligible to receive MOC credits, which fulfilled requirements for maintaining board certification in paediatrics.\
**Comparison:** usual practice\
**Description of comparison:** none\
**Duration:** 2 years\
**Vaccine target:** HPV vaccines\
**Disease targeted:** HPV infection\
**Number of doses:** 3 dosesOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSelection of the practice for the intervention or control condition was random.Allocation concealment (selection bias)Low riskIncluded centres allocated randomly.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskData available through a common electronic medical records\' system.Selective reporting (reporting bias)Low riskAll practices used the same electronic medical records\' system.Other biasLow riskNo evidence of other biases.[Rickert 2015](#CD011895-bbs2-0009){ref-type="ref-list"}MethodsRandomised trial conducted in the USAParticipants**Participants:** parents\
**Number per group:** parents were randomised into 4 groups: 106 parents in rhetorical question (RQ) intervention with 2‐sided message intervention; 114 parents in 2‐sided message‐only intervention; and controls 109 parents in RQ with 1‐sided message; 116 parents in 1‐sided message‐only.\
**Total number enrolled:** 445 parents\
**Study population:** parents of boys and girls aged 11--15 years who had not previously received the HPV vaccine.Interventions**Intervention:** 2 intervention groups:\
RQ plus a 2‐sided messageno RQ, 2‐sided message only.\
**Description:** The RQ approach involved first asking a general question that the participant was likely to endorse, followed by a more targeted question or request in a 2‐sided message. A 2‐sided message listed supporting arguments, but also acknowledged (and usually rebutted) ≥ 1 potential arguments against the advocated behaviour.\
**Duration:** 1 hour\
**Comparison:** 2 groups that received 1‐sided messages only:\
RQ plus a 1‐sided messageno RQ, 1‐sided message only.\
**Description of comparison:** The RQ involved asking a general question that the participant was likely to endorse, followed by a 1‐sdied message. A 1‐sided message presented only the arguments supporting the advocated behaviour.\
**Vaccine target:** HPV vaccine\
**Disease targeted:** cervical cancer\
**Number of doses:** not specifiedOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe randomisation was done into 4 groups, RQ intervention with 2‐sided message intervention, 2‐sided message‐only intervention, RQ with 1‐sided message, and 1‐sided message.Allocation concealment (selection bias)Low riskRandomisation was built into the programmes using a random numbers table.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up.Selective reporting (reporting bias)Unclear riskNo description.Other biasLow riskNo evidence of other biases.[Schwarz 2008](#CD011895-bbs2-0010){ref-type="ref-list"}MethodsRandomised trial conducted in the USAParticipants**Participants:** adolescents (girls and boys) and caregivers\
**Number per group:** 37 caregivers and 41 adolescents aged 10--18 years in intervention group and 39 caregivers and 39 adolescents aged 10--18 years in control group\
**Total number enrolled:** 328 children and 170 caregivers\
**Study population:** homeless shelter children and adolescents and their caregiversInterventions**Intervention:** hepatitis B education intervention\
**Description:** the videos were \"Respect Yourself/Protect Yourself\" by the Hepatitis Foundation International (to instruct the person about hepatitis B infection and the importance of hepatitis B vaccine).\
The interventions included: health education, cash incentives, and free vaccination. 1 of the interventions was health education on hepatitis B vaccine for caregivers and adolescents. The caregivers and adolescents were exposed to an educational video called \"Respect Yourself/Protect Yourself\" which educated the participants about hepatitis B infection and the importance of hepatitis B vaccination. After the video presentation, the research nurse reviewed the contents of the video with a 5‐minute PowerPoint summary and encouraged the participants to ask questions to increase their understanding of the information presented. The families were given the vaccine information sheet for hepatitis B. Thereafter, free vaccination was offered as an incentive.\
The investigators offered free hepatitis B vaccine, provided caregivers with USD 10, and gave adolescents and caregivers gift packages containing cosmetics for the adults and sweets and toothbrushes for the children. All families were instructed to return after 1 month for the second visit (second dose), and after 2 months for a third dose. During the second visit, the caregivers were paid USD 10 and during the third visit they were paid USD 30 and adolescents and caregivers were given gift packages for both visits.\
**Duration:** 21 months\
**Comparison 1:** usual practice\
**Description of comparison 1:** education about the deleterious health consequences of cigarette smoking.\
**Vaccine target:** hepatitis B\
**Disease targeted:** hepatitis B\
**Number of doses:** 3 dosesOutcomesHepatitis B vaccine uptake\
Hepatitis B knowledge scoreNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up.Selective reporting (reporting bias)Low riskStudy was free from selective outcome reporting.Other biasLow riskNo evidence of other bias.[Skinner 2000](#CD011895-bbs2-0011){ref-type="ref-list"}MethodsRandomised trial conducted in AustraliaParticipants**Participants:** school‐going girls and boys (class 7)\
**Number per group:** 458 students in intervention group and 467 students in control group\
**Total number enrolled:** 66 intervention schools (7588 students) AND 69 control schools (9823 students) aged 11--13 years\
**Study population:** Melbourne metropolitan secondary schools school‐going children in class 7Interventions**Intervention:** complex hepatitis B education\
**Description:** health education kit with 4‐lesson structured multi‐component intervention that included:\
resource fact sheet and assessment;an information video and questions designed to engage an adolescent audience;small group discussion;an activity to locate resource information on the Internet.\
The intervention group received the health educational in addition to the usual government student and parent information brochures.\
**Duration:** 1 year\
**Comparison:** simplified hepatitis B education\
**Description of comparison:** brochures were 1‐page folded coloured leaflets, outlining in simple terms, the risks of hepatitis B and benefits and adverse effects of vaccination.\
**Vaccine target:** hepatitis B vaccine\
**Disease targeted:** hepatitis B\
**Number of doses:** 3 dosesOutcomesHepatitis B vaccine uptake\
Hepatitis B vaccine knowledge and attitudeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom allocation to intervention and control was done.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskAll schools recruited were included in the analysis on an intention‐to‐treat basis.Selective reporting (reporting bias)Unclear riskNo description.Other biasLow riskNo evidence of other bias.[Staras 2015](#CD011895-bbs2-0012){ref-type="ref-list"}MethodsNon‐randomised trial in the USAParticipants**Participants:** girls and boys aged 11--17 years\
**Number per group:** 1387 girls and 1764 boys, 400 parents\
**Total number enrolled:** 2773 girls and 3350 boys assigned to 4 groups: postcard campaign, in‐clinic HIT system, postcard campaign and in‐clinic HIT system, and usual care.\
**Study population:** adolescents who were enrolled in Medicaid or Children's Health Insurance Program (CHIP) in June 2013; who had a residential zip code in North Central Florida defined as within Gainesville, Florida, or a surrounding Primary Care Service Area (Chiefland, Citra, Crescent City, Cross City, Interlachen, Keystone Heights, Lake Butler, Lake City, Live Oak, Mayo, Ocala, Palatka, Starke, Steinhatchee, and Williston); and had ≥ 1 regular clinic visit between 1 July 2011 and 1 August 2013.Interventions**Intervention:** multi‐level intervention called Protect Me from HPV, with 2 components: a system‐level postcard campaign and an in‐clinic health information technology (HIT) reminder system\
**Description:** the interventions were offered in 3 groups:\
postcard campaign;in‐clinic HIT system;postcard campaign and in‐clinic HIT system\
The postcard campaign contained healthcare information about vaccine benefits, costs, adverse effects, and safety and was designed to prompt parents and adolescents to discuss the vaccine with their doctor. The HIT system contained health risk questions for adolescents to verify vaccination history and indicate interest in learning about the vaccine. The HIT system summarised adolescent responses for providers in real time via colour‐coded system.\
**Duration:** 3 months\
**Comparison:** usual practice\
**Description:** Providers were asked to follow usual care for adolescents in this group\
**Vaccine target:** HPV vaccines\
**Disease targeted:** HPV infection\
**Number of doses:** 1 doseOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskNo randomisation of HIT. Thus it was possible that some of the effects of the HIT system could have been be attributed to differences between the HIT and non‐HIT provider practices or participants rather than the HIT system itself.Allocation concealment (selection bias)High riskThe HIT system was offered only to adolescents attending specific providers.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesHigh riskLike all single‐system records of vaccination, the Medicaid and CHIP records likely contain incomplete information as suggested by patient interactions with the HIT system. For example, adolescents who received the HPV vaccine at the Health Department may not have claimed through Medicaid and CHIP.Selective reporting (reporting bias)Low riskPotential for selection bias was evaluated by comparing vaccine initiation between HIT and non‐HIT providers.Other biasUnclear riskNo description.[Szilagyi 2015](#CD011895-bbs2-0013){ref-type="ref-list"}MethodsRandomised trial in the USAParticipants**Participants:** providers\
**Number per group:** PBRN consisted of 10 practices; 5 intervention and 5 controls while from the national paediatric continuity clinic PBRN (CORNET) consisted of 12 practices; 6 intervention, 6 controls.\
**Number enrolled:** 22 practices\
**Study population:** 22 practices were allocated in 1 of 2 PBRNs to provider prompts or standard‐of‐care control. 10 primary care practices participated, 5 intervention and 5 controls, each matched in pairs on urban, suburban, or rural location and practice type (paediatric or family medicine), from a PBRN in Greater Rochester, NY (GR‐PBRN); and 12 practices, 6 intervention, 6 controls, similarly matched, from a national paediatric continuity clinic PBRN (CORNET).Interventions**Intervention:** EHR prompt\
**Description:** the EHR display a prompt on the screen when a healthcare provider opens each of the patient\'s EMRs. In the study, all prompts used the same algorithm and displayed a list of vaccines due at that visit. Prompts did not generally show prior vaccinations and did not include standing orders. For each intervention practice, between 1‐ and 2‐hour educational sessions was given to the providers to inform them about EHR‐based prompts.\
**Duration:** 12‐month\
**Comparison:** usual practice\
**Description:** providers in the control practices received standard of care, which did not include prompts\
**Vaccine target:** Tdap, MCV4, HPV, and influenza vaccines\
**Disease targeted:** meningitis, HPV, influenza, tetanus, diphtheria, pertussis\
**Number of doses:** 3 doses for HPV. Others not specifiedOutcomesUptake of Tdap; MCV4; HPV1, 2, and 3; and influenza vaccinesNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSAS software program used to randomly allocate to the intervention or control.Allocation concealment (selection bias)Low riskUsing Stata 12.1, 1 author (AB) randomly assigned practices within each PBRN and practice pair to be an intervention or a standard of care control practice.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskHealthcare providers were unaware of group assignment and the intervention was delivered by trained patient immunisation navigators.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss of 1 practice pair from the GR‐PBRN and refusal rates were similar for intervention and control practices.Selective reporting (reporting bias)Low riskProbably no selective reporting.Other biasLow riskNo other bias.[Watson‐Jones 2012](#CD011895-bbs2-0014){ref-type="ref-list"}MethodsCluster‐randomised trial in TanzaniaParticipants**Participants:** girls enrolled in primary school grade 6 or girls born in 1998.\
**Number enrolled:** 134 schools (60 urban government, 60 rural government, and 14 private) and 5532 eligible girls\
**Study population:** in the city of Mwanza and the neighbouring district of Misungwi in northwest Tanzania, 134 primary schools were randomly assigned to class‐based (girls enrolled in primary school grade (class) 6) or age‐based (girls born in 1998; 67 schools per arm) vaccine delivery.Interventions**Intervention:** provision of HPV vaccine through a class‐based strategy (targeting girls in school class 6).\
**Comparison:** provision of HPV vaccine through an age‐based strategy (targeting girls born in 1998).\
**Description:** teachers, parents, and girls in the target vaccination group were provided with verbal and written information about HPV vaccination through school, parent, and community meetings; leaflets and posters; radio messages; and through community drama troupes.\
**Duration:** 12 months\
**Vaccine target:** HPV\
**Disease targeted:** cervical cancer\
**Number of doses:** 3 dosesOutcomesHPV vaccine uptake\
Adverse eventsNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Low riskAllocation done by an independent statistician.Blinding of participants and personnel (performance bias)   All outcomesLow riskThis was cluster randomised and the outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskHPV uptake is an objective outcome measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up.Selective reporting (reporting bias)Low riskNo selective reporting.Other biasLow riskNo other bias observed.[Wilson 2005](#CD011895-bbs2-0015){ref-type="ref-list"}MethodsNon‐randomised trial in the USAParticipants**Participants:** ninth grade and 12th grade girls and boys\
**Number per group:** 2652 students from intervention group (Missouri state) and 3810 students from the control group (Kansas state)\
**Total number enrolled:** 6462 student from 12 accepted (4 urban public, 4 suburban public, 2 rural public, and 2 private) were evaluated.\
**Study population:** ninth and 12th grade students attending schools in the Kansas City, Missouri metropolitan area both affected and unaffected by the hepatitis B vaccination school entry law.Interventions**Intervention:** school entry law mandating hepatitis B vaccination\
**Description:** hepatitis B vaccination required, by law, for seventh grade entry. The study compared vaccination coverage among adolescent students in ninth grade (affected by a new hepatitis B law) and 12th grade (not affected by the law) from 11 schools in 2 states of the USA. The intervention state mandated hepatitis B vaccination for elementary school entry in 1997 and for middle school in 1999 while in the control state, the elementary school did not mandate school entry vaccination.\
**Duration:** Missouri‐mandated hepatitis B vaccination for elementary school entry in 1997 and for middle school in 1999 and data collection occurred in 2003.\
**Comparison:** usual practice\
**Description:** no hepatitis B school entry law. Kansas had not mandated hepatitis B vaccination for elementary school entry at the time this study was conducted.\
**Vaccine target:** hepatitis B vaccine\
**Disease targeted:** hepatitis B\
**Number of doses: 3**OutcomesHepatitis B vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskThis is a non‐randomised study. However, it was a well conducted study that used \"retrospective design with purposive school sampling, using location of residence to determine study group. In each school, immunization records from a random sample of up to 75 students\" were reviewed.Allocation concealment (selection bias)High riskThis is a non‐randomised study. However, it was a well conducted study that used \"retrospective design with purposive school sampling, using location of residence to determine study group. In each school, immunization records from a random sample of up to 75 students\" were reviewed.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow risk99.5% of participants had outcome data available.Selective reporting (reporting bias)Low riskOutcomes/hypotheses were all reported.Other biasLow riskNo evidence of other biases.[Winer 2016](#CD011895-bbs2-0016){ref-type="ref-list"}MethodsCluster‐randomised trial in the USAParticipants**Participants:** parents\
**Number per group:** 43 parents in intervention group and 54 parents in control group\
**Total number enrolled:** 97 parents\
**Study population:** mother or female legal guardian of a girl aged 9--12 years enrolled in the Hopi TribeInterventions**Intervention:** educational presentations on HPV\
**Description:** PowerPoint presentation with information on HPV prevalence and transmission, HPV vaccine recommendations, dosage schedule, and vaccine efficacy and safety. An educational brochure with similar content was also created to accompany the presentation.\
Parents attended mother--daughter dinners featuring educational presentations for mothers on HPV. Educational PowerPoint presentations provided information on HPV prevalence and transmission, HPV vaccine recommendations, dosage schedule, vaccine efficacy, and vaccine safety. An educational brochure with similar content was created to accompany the presentation.\
**Duration:** 30--40 minutes\
**Comparison:** no education on HPV\
**Description of comparison:** parents attended mother--daughter dinners featuring educational presentations for mothers on juvenile diabetes. Educational PowerPoint presentations focused on risk factors for type 2 juvenile diabetes, healthy nutrition, physical activity, and what parents could do to prevent or manage diabetes for their children.\
**Vaccine target:** HPV vaccine\
**Disease targeted:** cervical cancer\
**Number of doses:** not specifiedOutcomesHPV vaccine uptakeNotes ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStudy randomly assigned 2 clusters to the intervention group and 2 to the control group.Allocation concealment (selection bias)Unclear riskNo description.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe outcome is an objective measure.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe outcome is an objective measure.Incomplete outcome data (attrition bias)   All outcomesLow riskNo attrition bias.Selective reporting (reporting bias)Unclear riskNo description.Other biasLow riskNo evidence of other biases.[^1]

Characteristics of excluded studies \[ordered by study ID\] {#CD011895-sec-0154}
===========================================================

StudyReason for exclusion[Anjum 2012](#CD011895-bbs2-0017){ref-type="ref-list"}Simple pre‐ and post cross‐sectional survey with no controls.[Bar‐Shain 2015](#CD011895-bbs2-0018){ref-type="ref-list"}Intervention was a reminder.[Bennett 2015](#CD011895-bbs2-0019){ref-type="ref-list"}Age of participants was 18--26 years, not separated to cater for 18--19 years.[Broutet 2013](#CD011895-bbs2-0020){ref-type="ref-list"}Review.[Catledge 2014](#CD011895-bbs2-0021){ref-type="ref-list"}Pre‐ and postsurvey.[Chan 2015](#CD011895-bbs2-0022){ref-type="ref-list"}Pre‐ and poststudy.[Chapman 2010](#CD011895-bbs2-0023){ref-type="ref-list"}Pre‐ and postcross‐sectional survey.[Chaves 2000](#CD011895-bbs2-0024){ref-type="ref-list"}The study is in Spanish[Chou 2014](#CD011895-bbs2-0025){ref-type="ref-list"}Pre‐ and postconsultation surveys.[Chung 2015](#CD011895-bbs2-0026){ref-type="ref-list"}Intervention was a reminder.[Dawson 2015](#CD011895-bbs2-0027){ref-type="ref-list"}Pre‐ and postintervention study.[Dempsey 2015a](#CD011895-bbs2-0028){ref-type="ref-list"}Pre‐ and postintervention study.[Dempsey 2015b](#CD011895-bbs2-0029){ref-type="ref-list"}Pre‐ and poststudy.[Donahue 2016](#CD011895-bbs2-0030){ref-type="ref-list"}Intervention was a reminder.[Dorji 2015](#CD011895-bbs2-0031){ref-type="ref-list"}Descriptive study, with no intervention and control arms.[Farmar 2016](#CD011895-bbs2-0032){ref-type="ref-list"}Pre‐ and postintervention study.[Fujiwara 2013](#CD011895-bbs2-0033){ref-type="ref-list"}Questionnaire survey, with no intervention and control.[Furlan 2010](#CD011895-bbs2-0034){ref-type="ref-list"}Descriptive study with no intervention.[Gargano 2014](#CD011895-bbs2-0035){ref-type="ref-list"}Descriptive study with no intervention.[Gillespie 2011](#CD011895-bbs2-0036){ref-type="ref-list"}Questionnaire survey in an ineligible age group.[Gordon 2013](#CD011895-bbs2-0037){ref-type="ref-list"}Descriptive study, with no intervention.[Gottvall 2010](#CD011895-bbs2-0038){ref-type="ref-list"}Quasi‐experimental intervention study.[Hadley 2014](#CD011895-bbs2-0039){ref-type="ref-list"}Descriptive study.[Hofman 2013](#CD011895-bbs2-0040){ref-type="ref-list"}Pre‐ and post‐test evaluation.[Hull 2016](#CD011895-bbs2-0041){ref-type="ref-list"}Pilot cross‐over study.[Iqbal 2016](#CD011895-bbs2-0042){ref-type="ref-list"}Age group is 11--25 years and data not stratified by age group.[Kim 2015](#CD011895-bbs2-0043){ref-type="ref-list"}Pre‐ and post‐test study.[Kwan 2011](#CD011895-bbs2-0044){ref-type="ref-list"}Pre‐ and postevaluation study.[Kwang 2016](#CD011895-bbs2-0045){ref-type="ref-list"}Pre‐ and poststudy in an ineligible age group.[Lai 2013](#CD011895-bbs2-0046){ref-type="ref-list"}Quasi‐experimental time series.[LaMontagne 2011](#CD011895-bbs2-0047){ref-type="ref-list"}Cross‐sectional study.[Marek 2012](#CD011895-bbs2-0048){ref-type="ref-list"}Simple pre--post survey.[Meneses Echavez 2015](#CD011895-bbs2-0049){ref-type="ref-list"}Pre‐ and postintervention with no control.[Moss 2012](#CD011895-bbs2-0050){ref-type="ref-list"}Pre‐ and postintervention survey.[Ortiz 2016](#CD011895-bbs2-0051){ref-type="ref-list"}Pilot cross‐sectional study.[Perkins 2016](#CD011895-bbs2-0052){ref-type="ref-list"}Cross‐sectional survey.[Pierre‐Victor 2017](#CD011895-bbs2-0053){ref-type="ref-list"}Pre‐ and poststudy.[Reiter 2011](#CD011895-bbs2-0054){ref-type="ref-list"}Pre‐ and postevaluation study.[Ruffin 2015](#CD011895-bbs2-0055){ref-type="ref-list"}Intervention was a reminder.[Sales 2011](#CD011895-bbs2-0056){ref-type="ref-list"}Pre‐ and poststudy.[Soldan 2006](#CD011895-bbs2-0057){ref-type="ref-list"}Review.[Spleen 2012](#CD011895-bbs2-0058){ref-type="ref-list"}Pretest/post‐test assessment.[Stokley 2015](#CD011895-bbs2-0059){ref-type="ref-list"}Review.[Szilagyi 2011](#CD011895-bbs2-0060){ref-type="ref-list"}Intervention was a reminder.[Tiro 2016](#CD011895-bbs2-0061){ref-type="ref-list"}Pre‐ and postsurvey.[Unti 1997](#CD011895-bbs2-0062){ref-type="ref-list"}Pre‐ and postsurvey.[Won 2015](#CD011895-bbs2-0063){ref-type="ref-list"}Outcomes were trust and participation in school‐located immunisation programmes, and none of our outcomes of interest was reported.[Zhou 2003](#CD011895-bbs2-0064){ref-type="ref-list"}Pre‐ and postintervention survey.
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[Dempsey 2018](#CD011895-bbs2-0065){ref-type="ref-list"}MethodsCluster‐randomised trial in the USAParticipants**Participants:** providers\
**Number per group:** 8 providers in intervention group and 8 providers in control group\
**Total number enrolled:** 188 providers\
**Study population:** 16 practices (4 family medicine and 12 paediatrics) that included 188 medical professionals with ≥ 400 active adolescents (aged 11--17 years).Interventions**Intervention:** 5‐component communication intervention on HPV\
**Description:** the intervention included the following:\
a fact sheet library that practices used to create practice specific fact sheets about HPV infection and vaccination;a parent education website called \"iVac\" that created individually customized information about HPV vaccination;a series of disease images depicting diseases associated with HPV;a decision aid for HPV vaccination;communication training to improve healthcare professionals\' vaccine recommendation practices.\
**Duration:** 6 months\
**Comparison:** no communication on HPV\
**Description of comparison:** practices in the control arm continued usual care with regard to communication about HPV vaccines.\
**Vaccine target:** HPV vaccine, meningococcal conjugate vaccine and ≥ 1 dose of the HPV vaccine series\
**Disease targeted:** cervical cancer and meningitis and tetanus, pertussis and diphtheria\
**Number of doses:** ≥ 1 dose the HPV vaccine seriesOutcomesHPV vaccine uptake\
Uptake of 2 other adolescent vaccines, i.e. meningococcal conjugate vaccine (MenACWY) and the tetanus--diphtheria--acellular pertussis vaccine (Tdap)Notes [Esposito 2018](#CD011895-bbs2-0066){ref-type="ref-list"}MethodsRandomised trial in ItalyParticipants**Participants:** adolescents aged 11--13 years\
**Number per group:** 334 participants in no intervention group, 281 participants in website educational programme only, and 302 participants in website educational programme plus the face‐to‐face lesson\
**Total number enrolled:** 917 adolescents\
**Study population:** over 1 school year, involving 4 secondary schools for adolescents aged 11--13 years and 8 schools for adolescents 14--18 years old in Milan, Italy.Interventions**Intervention:** education intervention on adolescent vaccines\
**Description:**\
registration of vaccination coverage and attitudes toward vaccination at the beginning and at the end of the school year plus participation in a presentation and access to a specific website dedicated to vaccines and vaccination;the procedures described in arm 2 plus participation in a lecture on vaccines and vaccination from medical experts in classrooms.\
**Duration:** 1 school year\
**Comparison:** no education intervention on adolescent vaccines\
**Description of comparison:** registration of vaccination coverage and attitudes toward vaccination at the beginning and at the end of the school year, but no intervention\
**Vaccine target:** diphtheria, tetanus, pertussis and HPV vaccines\
**Disease targeted:** cervical cancer and tetanus, pertussis and diphtheria\
**Number of doses:** not specifiedOutcomesAdolescent vaccines uptake\
Knowledge and attitude on adolescent vaccinesNotes [^2]
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[Skinner 2015](#CD011895-bbs2-0067){ref-type="ref-list"}Trial name or titleHPV.eduMethodsCluster‐randomised trialParticipants**Participants:** adolescents in their first year of high school (year 8 in participating states)\
**Number enrolled:** 40 schools with year‐8 enrolments above 100 students\
**Study population:** adolescents attending high school in each of 2 states, western Australia and south AustraliaInterventions**Intervention:** 3 main components: adolescent intervention; HPV vaccine parent/adolescent decision support tool; and logistical strategies; methods for increasing consent form return such as direct mail‐out of forms to parents.\
**Description:**\
adolescent intervention; education taught through the school in an interactive lesson;HPV vaccine parent/adolescent decision support tool; designed for use by both adolescents and parents together in the home environment; andlogistical strategies; methods for increasing consent form return such as direct mail‐out of forms to parents.\
**Duration:** conducted over 2 school years: 2013 and 2014.\
**Comparison:** usual practice\
**Vaccine target:** HPV vaccination\
**Disease targeted:** cervical cancer\
**Number of doses:** no descriptionOutcomesHPV vaccine uptake\
HPV vaccination knowledgeStarting date1 February 2013Contact informationProf Rachel Skinner\
Discipline of Paediatrics and Child Health, University of Sydney, Children\'s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2054, Australia\
Email: Rachel.Skinner\@health.nsw.gov.auNotesTrial registered on ANZCTR with registration number ACTRN12614000404628[^3]

New author added during the review process (i.e. Valantine N Ndze).In the review, we did not conduct subgroup and sensitivity analyses, as specified in the protocol, due to lack of data. See Table 1 for methods specified in the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), but not used in the review.We removed adverse events following immunisation as an outcome as we realised posthoc that it was not a relevant outcome for this review.

LA, BK, GH, and CW conceived the review, participated in the development of the protocol ([Abdullahi 2015](#CD011895-bbs2-0131){ref-type="ref-list"}), and approved the final version for publication.

LA, BK, VN, GH, and CW participated in the review and approved the final version for publication.
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Department for International Development, UK.Project number 300342‐104
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[^1]: CDC: Centers for Disease Control and Prevention; CHIP: Children\'s Health Insurance Program; EHR: electronic health record; HIT: health information technology; HPV: human papillomavirus; MCV4: meningococcal conjugate vaccine; MOC: maintenance of certification; PBRN: practice‐based research network; RQ: rhetorical questions; Tdap: tetanus--diphtheria--acellular--pertussis.

[^2]: HPV: human papillomavirus.

[^3]: HPV: human papillomavirus.
